0001144204-19-025271.txt : 20190510 0001144204-19-025271.hdr.sgml : 20190510 20190510161103 ACCESSION NUMBER: 0001144204-19-025271 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190510 DATE AS OF CHANGE: 20190510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABEONA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000318306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 830221517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15771 FILM NUMBER: 19815009 BUSINESS ADDRESS: STREET 1: 3333 LEE PARKWAY STREET 2: SUITE 600 CITY: DALLAS STATE: TX ZIP: 75219 BUSINESS PHONE: 2149055100 MAIL ADDRESS: STREET 1: 3333 LEE PARKWAY STREET 2: SUITE 600 CITY: DALLAS STATE: TX ZIP: 75219 FORMER COMPANY: FORMER CONFORMED NAME: PLASMATECH BIOPHARMACEUTICALS INC DATE OF NAME CHANGE: 20140922 FORMER COMPANY: FORMER CONFORMED NAME: ACCESS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960209 FORMER COMPANY: FORMER CONFORMED NAME: CHEMEX PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 10-Q 1 tv520699_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to _________________

Commission file number 001-15771

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		83-0221517
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer I.D. No.)

1330 Avenue of the Americas, 33^rd Floor, New York, NY 10019

(Address of principal executive offices, zip code)

(646) 813-4712

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨		Accelerated filer þ
Non-accelerated filer ¨		Smaller reporting company þ
		Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No þ

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		ABEO		Nasdaq Capital Markets

The number of shares outstanding of the registrant’s common stock as of May 6, 2019 was 49,162,047 shares.

ABEONA THERAPEUTICS INC.

INDEX

		Page No.

PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements:

	Condensed Consolidated Balance Sheets at March 31, 2019 (Unaudited) and December 31, 2018	3

	Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2019 and 2018	4

	Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) for the three months ended March 31, 2019 and 2018	5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2019 and 2018	6

	Notes to Condensed Consolidated Financial Statements (Unaudited) for the three months ended March 31, 2019 and 2018	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Item 4.	Controls and Procedures	17

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	18

Item 1A.	Risk Factors	18

Item 6.	Exhibits	19

SIGNATURES		20

CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING INFORMATION

FOR THE PURPOSE OF “SAFE HARBOR” PROVISIONS OF THE

PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This Form 10-Q (including information incorporated by reference) contains statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “could,” “would,” “seeks,” “estimates,” and variations of such words and similar expressions, and the negatives thereof, are intended to identify such forward-looking statements. We caution readers not to place undue reliance on any such “forward-looking statements,” which speak only as of the date made, and advise readers that these forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by us that are difficult to predict. Various factors, some of which are beyond our control, could cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. All such forward-looking statements, whether written or oral, and whether made by us or on our behalf, are expressly qualified by these cautionary statements and any other cautionary statements that may accompany the forward-looking statements. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this report, except as may otherwise be required by the federal securities laws.

Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to a number of factors. Important factors that could affect performance and cause results to differ materially from management’s expectations are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form 10-K for the fiscal year ended December 31, 2018, as updated from time to time in the Company’s Securities and Exchange Commission filings, including this Form 10-Q. These factors include: our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing; our ability to raise capital; our ability to fund our operating expenses and capital expenditure requirements for at least the next 12 months with our existing cash and cash equivalents; our expectation that we will continue to incur losses; our belief that we will expend substantial funds to conduct research and development programs; our future ability to achieve profitability at all or on a sustained basis; our cash burn rate; the dilutive effect that raising additional funds by selling additional equity securities would have on the relative equity ownership of our existing investors; our belief that we have a rich pipeline of products and product candidates; our ability to continue to develop our novel adeno-associated virus (“AAV”)-based gene therapy platform technology to treat neurologic disorders, cystic fibrosis and eye disorders in human subjects; our belief that EB-101 could potentially benefit patients with recessive dystrophic epidermolysis bullosa (“RDEB”); our ability to initiate a Phase III clinical trial for patients with RDEB; our ability to complete enrollment of patients into clinical trials to secure sufficient data to assess efficacy and safety; our belief that AAV treatment could potentially benefit patients with Sanfilippo syndrome type A (“MPS IIIA”) and Sanfilippo syndrome type B (“MPS IIIB”); our ability to add clinical sites and identify additional patients for our Phase I/II clinical trial for patients with MPS IIIA and MPS IIIB; our ability to continue to secure and maintain regulatory designations for our product candidates; our ability to develop manufacturing capability compliant with current good manufacturing practices for our product candidates; our ability to manufacture gene therapy products and produce an adequate product supply to support clinical trials and potentially future commercialization; our ability to secure timely regulatory review related to our clinical program; our belief in the adequacy of the data from clinical trials in EB-101 and expansion cohort of our Phase I/II clinical trial in ABO-102 (AAV-SGSH) for MPS IIIA, together with the data generated in the program to date, to support regulatory approvals; our intellectual property position and our ability to obtain, maintain and enforce intellectual property protection and exclusivity for our proprietary assets; the rate and degree of market acceptance of our product candidates for any indication once approved; our estimates regarding the size of the potential markets for our product candidates, the strength of our commercialization strategies and our ability to serve and supply those markets; our ability to meet our obligations contained in license agreements to which we are party; and the terms of future licensing arrangements or collaborations.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Abeona Therapeutics Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	March 31, 2019			December 31, 2018
	(Unaudited)
ASSETS

Current assets:
Cash and cash equivalents	$	25,924,000		$	18,750,000
Short-term investments		42,387,000			66,218,000
Receivables		38,000			81,000
Prepaid expenses and other current assets		3,372,000			3,802,000
Total current assets		71,721,000			88,851,000

Property and equipment, net		10,356,000			9,443,000
Right-of-use lease assets		8,749,000			-
Licensed technology, net		41,697,000			43,042,000
Goodwill		32,466,000			32,466,000
Other assets and restricted cash		1,147,000			597,000
Total assets	$	166,136,000		$	174,399,000

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	4,189,000		$	6,122,000
Accrued expenses		5,241,000			3,936,000
Current portion of lease liability		1,690,000			-
Current portion of payable to licensor		10,000,000			10,000,000
Deferred revenue		296,000			296,000
Total current liabilities		21,416,000			20,354,000

Long-term lease liabilities		6,927,000			-
Payable to licensor, net of current portion		20,000,000			20,000,000
Total liabilities		48,343,000			40,354,000

Commitments and contingencies
Stockholders' equity:
Common stock - $0.01 par value; authorized 200,000,000 shares; issued and outstanding 47,949,694 at March 31, 2019; issued and outstanding 47,944,486 at December 31, 2018		479,000			479,000
Additional paid-in capital		546,057,000			543,754,000
Accumulated deficit		(428,743,000	)		(410,188,000	)
Total stockholders' equity		117,793,000			134,045,000
Total liabilities and stockholders' equity	$	166,136,000		$	174,399,000

The accompanying notes are an integral part of these condensed consolidated statements.

Abeona Therapeutics Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

	For the three months ended March 31,
	2019			2018
Revenues:
Foundation revenues	$	-		$	481,000
Royalties		-			50,000
Total revenues		-			531,000

Expenses:
Research and development		11,737,000			8,162,000
General and administrative		5,659,000			2,878,000
Depreciation and amortization		1,658,000			174,000
Total expenses		19,054,000			11,214,000

Loss from operations		(19,054,000	)		(10,683,000	)

Interest and miscellaneous income		499,000			156,000
Interest and other expense		-			(3,000	)
Net loss	$	(18,555,000	)	$	(10,530,000	)

Basic and diluted loss per common share	$	(0.39	)	$	(0.22	)

Weighted average number of common shares outstanding – basic and diluted		47,948,421			47,060,523

The accompanying notes are an integral part of these condensed consolidated statements.

Abeona Therapeutics Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

					Additional					Total
	Common Stock				Paid-in		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Equity
Balance, December 31, 2017 - as reported		46,888,108	$	469,000	$	529,421,000	$	(359,792,000	)	$	170,098,000
Cumulative effect adjustment of ASC 606 on January 1, 2018		-		-		-		6,275,000			6,275,000
Stock-based compensation expense		-		-		1,900,000		-			1,900,000
Restricted stock-based compensation expense		-		-		172,000		-			172,000
Common stock issued for:
- cash exercise of options		267,196		3,000		1,682,000		-			1,685,000
- exercise of $5.00 warrants		28,874		-		144,000		-			144,000
- cashless warrant exercises		48,762		-		-		-			-
Net loss		-		-		-		(10,530,000	)		(10,530,000	)
Balance, March 31, 2018		47,232,940	$	472,000	$	533,319,000	$	(364,047,000	)	$	169,744,000

Balance, December 31, 2018 - as reported		47,944,486	$	479,000	$	543,754,000	$	(410,188,000	)	$	134,045,000
Stock-based compensation expense		-		-		2,103,000		-			2,103,000
Restricted stock-based compensation expense		-		-		172,000		-			172,000
Common stock issued for cash exercise of options		5,208		-		28,000		-			28,000
Net loss		-		-		-		(18,555,000	)		(18,555,000	)
Balance, March 31, 2019		47,949,694	$	479,000	$	546,057,000	$	(428,743,000	)	$	117,793,000

The accompanying notes are an integral part of these condensed consolidated statements.

Abeona Therapeutics Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	For the three months ended March 31,
	2019			2018
Cash flows from operating activities:
Net loss	$	(18,555,000	)	$	(10,530,000	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		1,658,000			174,000
Stock-based compensation expense		2,103,000			1,900,000
Restricted stock-based compensation expense		172,000			172,000
Non-cash earnings on investments		(169,000	)		-
Change in operating assets and liabilities:
Receivables		43,000			43,000
Prepaid expenses and other current assets		430,000			643,000
Right-of-use lease assets and other assets		150,000			-
Accounts payable, accrued expenses and lease liabilities		(910,000	)		3,516,000
Net cash used in operating activities		(15,078,000	)		(4,082,000	)

Cash flows from investing activities:
Capital expenditures		(1,226,000	)		(3,502,000	)
Proceeds from maturities of short-term investments		24,000,000			-
Net cash provided by (used in) investing activities		22,774,000			(3,502,000	)

Cash flows from financing activities:
Proceeds from exercise of $5.00 warrants		-			144,000
Proceeds from exercise of stock options		28,000			1,685,000
Net cash provided by financing activities		28,000			1,829,000

Net increase (decrease) in cash, cash equivalents and restricted cash		7,724,000			(5,755,000	)
Cash, cash equivalents and restricted cash at beginning of period		19,310,000			138,030,000
Cash, cash equivalents and restricted cash at end of period	$	27,034,000		$	132,275,000

Supplemental cash flow information:
Cash and cash equivalents	$	25,924,000		$	131,995,000
Restricted cash		1,110,000			280,000
Total cash, cash equivalents and restricted cash	$	27,034,000		$	132,275,000

Cash paid for interest	$	-		$	3,000

The accompanying notes are an integral part of these condensed consolidated statements.

ABEONA THERAPEUTICS INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1 – NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

Background

Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”), ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”), and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We also are developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases. In addition, we are developing next generation AAV-based gene therapy though our novel AIM™ vector platform programs. Our efforts have been principally devoted to research and development, resulting in significant losses.

Basis of Presentation

The condensed consolidated balance sheet as of March 31, 2019, the condensed consolidated statements of operations for the three months ended March 31, 2019 and 2018, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2019 and 2018, and the condensed consolidated statements of cash flows for the three months ended March 31, 2019 and 2018, were prepared by management without audit. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended December 31, 2018. The results of operations for the period ended March 31, 2019 are not necessarily indicative of the operating results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2018 contains financial information taken from the audited Abeona consolidated financial statements as of that date.

As of March 31, 2019, we had 5,696,353 options and 1,820,686 warrants that were not included in the EPS calculation as their effect would be antidilutive. As of March 31, 2018, we had 5,807,531 options and 2,838,576 warrants that were not included in the EPS calculation as their effect would be antidilutive.

Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, as amended (ASC 606). At year-end 2018, we determined that we should adjust the amounts originally reported for the quarters ended March 31, 2018 and June 30, 2018 to correct for an error in the determination of the cumulative effect related to the adoption of ASC 606 as of January 1, 2018. The adjusted amounts for March 31, 2018 reflect a $2,067,000 reduction in foundation revenues and corresponding increases in the loss from operations and net loss of $2,067,000 and an increase in the diluted loss per share of $0.04, as compared to the originally reported amounts. The adjusted amounts for June 30, 2018 reflect a $543,000 reduction in foundation revenues and corresponding increases in the loss from operations and net loss of $543,000 and an increase in the diluted loss per share of $0.01, as compared to the originally reported amounts

Uses and Sources of Liquidity

The financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.

As of March 31, 2019, we had cash, cash equivalents and short-term investments of $68.3 million and net assets of $117.8 million. For the three months ended March 31, 2019, we had cash outflows from operations of $15.1 million. We believe we have sufficient resources to fund our business operations for the foreseeable future. However, we have implemented a multi-faceted program to secure sufficient liquidity through at least the end of 2020.

This program considers the possibility of accessing additional equity funding from current or new stockholders, out-licensing technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount and sales of assets. We believe that we will be able to complete our liquidity program and will have sufficient funding to support planned expenditure commitments and our planned level of growth, and therefore we believe it is appropriate to prepare the financial statements on the going concern basis.

NOTE 2 – NEW ACCOUNTING STANDARD IMPLEMENTED

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases, as amended (“ASC 842”), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. We adopted the provisions of ASC 842 effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard as of the effective date without adjusting the comparative periods presented. As a result of the adoption, we recorded operating lease right-of-use assets of $8.9 million and operating lease liabilities of $8.9 million. The adoption had an immaterial impact on our net assets as of March 31, 2019. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed us to carry forward the historical lease classification.

Additional information and disclosures required by this new standard are contained in Note 7.

NOTE 3 – SHORT-TERM INVESTMENTS

The following table summarizes the available-for-sale investments held:

Description		March 31, 2019				December 31, 2018
U.S. government and agency securities and treasuries		$	42,387,000			$	66,218,000

The amortized cost of the available-for-sale investments is adjusted for amortization of premiums and accretion of discounts to maturity. There were no material realized gains or losses recognized on the sale or maturity of available-for-sale investments during the three months ended March 31, 2019.

NOTE 4 – LICENSED TECHNOLOGY

On November 4, 2018, we entered into a license agreement with REGENXBIO to obtain rights to an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO’s NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. In return for these rights, REGENXBIO will receive a guaranteed $20 million upfront payment, $10 million of which was paid on signing of the agreement on November 4, 2018 and $10 million of which will be paid by November 4, 2019. In addition, REGENXBIO will receive a total of $100 million in annual fees, payable upon the second through sixth anniversaries of the agreement, $20 million of which is guaranteed. REGENXBIO is also eligible to receive potential commercial milestone payments of up to $60 million as well as low double-digit royalties on net sales of products incorporating the licensed intellectual property. The license is amortized over the life of the patent of eight years.

On August 3, 2016, we announced that we entered into an agreement (the “EB Agreement”) with EB Research Partnership (“EBRP”) and Epidermolysis Bullosa Medical Research Foundation (“EBMRF”) to collaborate on gene therapy treatments for EB. The EB Agreement became effective August 3, 2016, on the execution of two licensing agreements with The Board of Trustees of Leland Stanford Junior University (“Stanford”). We also entered into a license with Stanford for the AAV-based gene therapy EB-201 (AAV DJ COL7A1) technology and are performing preclinical development and clinical trials of a gene therapy treatment for EB based upon such in-licensed technology. EB-201 (AAV DJ COL7A1) is a preclinical candidate targeting a novel, AAV-mediated gene editing and delivery approach (known as homologous recombination) to correct gene mutations in skin cells (keratinocytes) for patients with RDEB. The licenses are amortized over the life of the license of 20 years.

On May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children’s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is amortized over the life of the license of 20 years.

Licensed technology consists of the following:

	March 31, 2019		December 31, 2018
Licensed technology	$	44,859,000	$	44,859,000
Less accumulated amortization		3,162,000		1,817,000
Licensed technology, net	$	41,697,000	$	43,042,000

The aggregate estimated amortization expense for intangible assets remaining as of March 31, 2019 is as follows:

2019, remainder	$	4,033,000
2020		5,378,000
2021		5,378,000
2022		5,378,000
2023		5,378,000
Thereafter		16,152,000
Total	$	41,697,000

Amortization on licensed technology was $1,345,000 and $87,000 for the three months ended March 31, 2019 and 2018, respectively.

NOTE 5 – FAIR VALUE MEASUREMENTS

We calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of receivables, prepaid expenses, other assets, accounts payable, accrued expenses, payable to licensor and deferred revenue approximate their carrying amounts due to the relatively short maturity of these instruments.

U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.

Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of March 31, 2019 and December 31, 2018 are summarized below:

Description	March 31, 2019		Level 1		Level 2		Level 3		Total Gains/(Losses)
Recurring
Assets:
Short-term investments	$	42,387,000	$	-	$	42,387,000	$	-	$	-

Non-recurring
Assets:
Licensed technology, net	$	41,697,000	$	-	$	-	$	41,697,000	$	-
Goodwill		32,466,000		-		-		32,466,000		-

Description	December 31, 2018		Level 1		Level 2		Level 3		Total Gains/(Losses)
Recurring
Assets:
Short-term investments	$	66,218,000	$	-	$	66,218,000	$	-	$	-

Non-recurring
Assets:
Licensed technology, net	$	43,042,000	$	-	$	-	$	43,042,000	$	-
Goodwill		32,466,000		-		-		32,466,000		-

NOTE 6 – STOCK-BASED COMPENSATION

The following table summarizes stock-based option compensation for the three months ended March 31, 2019 and 2018:

	For the three months ended March 31,
	2019		2018
Research and development	$	1,032,000	$	1,056,000
General and administrative		1,071,000		844,000
Stock-based compensation expense included in operating expense		2,103,000		1,900,000

Total stock-based compensation expense		2,103,000		1,900,000
Tax benefit		-		-
Stock-based compensation expense, net of tax	$	2,103,000	$	1,900,000

We estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:

Expected volatility – we estimate the volatility of our share price at the date of grant using a “look-back” period which coincided with the expected term, defined below. We believe using a “look-back” period which coincides with the expected term is the most appropriate measure for determining expected volatility.

Expected term – we estimate the expected term using the “simplified” method, as outlined in Staff Accounting Bulletin No. 107, “Share-Based Payment.”

Risk-free interest rate – we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term of the options in effect at the time of grant.

Dividends – we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare a dividend.

We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:

	For the three months ended March 31,
	2019			2018
Expected volatility		109	%		109	%
Expected term		5 years			5 years
Risk-free interest rate		2.46	%		2.37	%
Expected dividend yield		0	%		0	%

For the three months ended March 31, 2019, we granted 201,000 stock options and the weighted-average fair value was $5.29 and the weighted-average exercise price was $6.69. For the three months ended March 31, 2018, we granted 645,000 stock options and the weighted-average fair value was $10.83 and the weighted-average exercise price was $13.72.

The following table summarizes restricted common stock compensation expense for the three months ended March 31, 2019 and 2018:

	For the three months ended March 31,
	2019		2018
Research and development	$	-	$	-
General and administrative		172,000		172,000
Stock-based compensation expense included in operating expense		172,000		172,000

Total stock-based compensation expense		172,000		172,000
Tax benefit		-		-
Stock-based compensation expense, net of tax	$	172,000	$	172,000

We did not grant any common stock to directors or employees during the three months ended March 31, 2019 and 2018.

NOTE 7 – OPERATING LEASES

We lease space under non-cancelable operating leases for manufacturing and laboratory facilities and administrative offices in Cleveland as well as administrative offices in New York. The leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office space in Dallas and Madrid, Spain as well as certain office equipment under operating leases, which have a non-cancelable lease term of less than one year and therefore, we have elected the practical expedient to exclude these short-term leases from our right-of-use assets and lease liabilities.

Most leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal period in our lease term.

As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.

Components of lease cost are as follows:

	Three months ended March 31, 2019
Operating lease cost	$	289,000
Variable lease cost	$	73,000
Short-term lease cost	$	47,000

The following table presents information about the amount and timing of cash flows arising from operating leases as of March 31, 2019:

Maturity of lease liabilities:
2019, remainder	$	1,266,000
2020		1,699,000
2021		1,713,000
2022		1,727,000
2023		1,741,000
Thereafter		3,667,000
Total undiscounted operating lease payments		11,813,000
Less: imputed interest		3,196,000
Present value of operating lease liabilities	$	8,617,000

Balance sheet classification:
Current portion of lease liability	$	1,690,000
Long-term lease liability		6,927,000
Total operating lease liabilities	$	8,617,000

Other information:
Weighted-average remaining lease term for operating leases		82 months
Weighted-average discount rate for operating leases		9.6	%

NOTE 8 – COMMITMENTS AND CONTINGENCIES

On January 18, 2018, William Mahon, a Company stockholder, served a demand upon the Company’s board of directors (the “Board”) pursuant to Section 220 of the Delaware General Corporation Law (the “Demand”) seeking to inspect certain of the Company’s books and records. Generally, the Demand’s stated purpose was to investigate allegedly excessive compensation awarded to non-employee Board members for the fiscal years 2015–2017. The Board denied the allegations in the Demand, and agreed to provide limited books and records to Mahon. On September 17, 2018, another Company stockholder, Francisco Dos Ramos, filed a stockholder derivative complaint in the Delaware Chancery Court (the “Dos Ramos Action”) against Steven Rouhandeh, Frank Carsten Thiel, Mark Alvino, Stefano Buono, Stephen Howell, Richard Van Duyne, and Todd Wider as defendants, and the Company as nominal defendant (the “Dos Ramos Defendants”). Dos Ramos generally alleges that the Board breached its fiduciary duties, were unjustly enriched, and committed corporate waste by approving allegedly excessive compensation to non-employee Board members for the fiscal years 2015–2017. Dos Ramos generally seeks disgorgement of the allegedly improper payments to the Board, money damages, an order requiring corporate governance reforms, costs and attorneys’ fees. On November 28, 2018, Mahon filed a stockholder derivative complaint (the “Mahon Action”) in the United States District Court for the District of Delaware (the “District Court”) against Mark Ahn, Mark Alvino, Jeffrey Davis, Stephen Howell, Todd Wider, and Steven Rouhandeh, as defendants, and the Company as a nominal defendant (“Mahon Defendants”). The allegations in the Mahon Action are substantially similar to those set forth in his Demand, as well as those in the Dos Ramos Action. Mahon generally seeks the disgorgement of the allegedly improper payments to the Board, a constructive trust, money damages, costs and attorneys’ fees. On December 6, 2018, Mahon and the Mahon Defendants filed a joint motion for preliminary approval of settlement, along with a stipulation of settlement (the “Stipulation”) intending to settle all claims asserted in the Mahon Action.

On January 8, 2019, the District Court approved the parties’ notice of settlement, enjoining all Company stockholders from commencing or further prosecuting any claims asserted in the Mahon Action, and scheduled a settlement approval hearing for May 1, 2019. On January 25, 2019, the Chancery Court entered an order staying the Dos Ramos Action until May 8, 2019—one week after the May 1, 2019 settlement hearing in the Mahon Action. On May 2, 2019 the District Court entered an Order and Final Judgment approving the Stipulation.

On October 22, 2018, EB Research Partnership, Inc. (“EBRP”) served upon the Company a Request for Arbitration (the “Request”), alleging that the Company is in breach of an Agreement executed in July 2016 (the “Agreement”) between and among the Company, EBRP, and Epidermolysis Bullosa Medical Research Foundation (“EBMRF”). EBRP alleges that Abeona has refused to lift trading restrictions on certain shares of Abeona common stock issued to EBRP, purportedly in breach of the Agreement. On November 21, 2018, the Company filed an action in the United States District Court for the Southern District of New York seeking a declaration that it is not required to arbitrate its dispute with EBRP on the basis that the Agreement is void for lack of consideration. On February 4, 2019, the court granted EBRP and EBMRF’s motion to compel arbitration. EBMRF was subsequently joined as a party to the arbitration. The parties submitted briefs to the arbitrator on March 18 and April 18, 2019. The dispute is pending before the arbitrator and a decision is expected on or before May 20, 2019.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”), ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”), and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We also are developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases. In addition, we are developing next generation AAV-based gene therapies though our novel AIM™ vector platform programs. We believe our product candidates are eligible for orphan drug designation, breakthrough therapy designation, or other expedited review processes in the U.S., Europe or Japan. We hold several U.S. and EU regulatory designations for five product candidates as follows:

Our robust and diverse pipeline features early-stage and late-stage candidates with the potential to transform the treatment of devastating genetic diseases, and we are conducting clinical trials in the U.S. and abroad.

Our Mission and Strategy

Abeona is at the forefront of gene and cell therapy research and development. We are a fully-integrated company featuring therapies in clinical development, in-house manufacturing facilities, a robust pipeline, and scientific, clinical, and commercial leadership. We see our mission as working together to create, develop, manufacture and deliver gene and cell therapies for people impacted by serious diseases. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies that address the underlying cause of a broad spectrum of rare genetic diseases where no effective treatment options exist today.

Since our last fiscal year, we made significant progress toward fulfilling our goal of harnessing the promise of genetic medicine to transform the lives of people impacted by serious diseases and redefine the standard of care through gene and cell therapies. Our strategy to achieve this goal consists of:

Advancing our Clinical Gene and Cell Therapy Programs and Research and Development with a Focus on Rare and Orphan Diseases.

We have three programs in clinical development—EB-101, ABO-101 and ABO-102—and a pipeline of additional earlier stage programs. Our programs are focused on rare serious diseases. Through our gene and cell therapy expertise in research and development, we are positioned to rapidly introduce meaningful therapeutics to transform the standard of care in devastating diseases and establish our leadership position in the field.

Applying Novel Next Generation AIM™ Vector Technology to Develop New In-Vivo Gene Therapies.

We are researching and developing the next generation of AAV gene therapy using our novel capsids developed from the AIM™ Vector Technology Platform. We aim to continue to develop chimeric AAV capsids capable of improved tissue targeting for various indications and potentially evading immunity to wildtype AAV vectors.

Establishing Leadership Position in Commercial-Scale Gene and Cell-Therapy Manufacturing.

We established current Good Manufacturing Practice (“cGMP”), clinical-scale manufacturing capabilities for gene-corrected cell therapy and AAV-based gene therapies in our state-of-the-art Cleveland, OH facility. We believe that our platform provides us with distinct advantages, including flexibility, scale, reliability, and the potential for reduced development risk, cost, and faster times to market. We have focused on establishing internal Chemistry, Manufacturing and Controls (“CMC”) capabilities that drive value for our organization through process development, assay development and manufacturing. We have also deployed robust quality systems governing all aspects of product lifecycle from preclinical through commercial stage.

Establishing Additional Gene and Cell Therapy Franchises and Adjacencies through In-Licensing and Strategic Partnerships.

We seek to be the partner of choice in rare disease and have closely collaborated with leading academic institutions, key opinion leaders, patient foundations and industry partners to generate novel intellectual property, accelerate research and development, and understand the needs of patients and their families.

Maintaining and Growing IP Portfolio.

We strive to have a leading intellectual property portfolio. To that end, we seek patent rights for various aspects of our programs, including vector engineering and construct design, our production process, and all features of our clinical products including composition of matter and method of administration and delivery. We expect to continue to expand our intellectual property portfolio by aggressively seeking patent rights for promising aspects of our product engine and product candidates.

RESULTS OF OPERATIONS

Foundation revenues relate to a collaborative agreement between us and nine Sanfilippo foundations to provide up to approximately $13.9 million of grants to us in installments for the advancement of our clinical stage gene therapies for MPS IIIA and MPS IIIB, subject to the achievement of certain milestones. We have received $5.7 million of such grants as of March 31, 2019. Our foundation revenue was $0 in the first quarter of 2019 and $0.5 million in the first quarter of 2018. The cash received upfront from the foundations is deferred on the condensed consolidated balance sheet until the costs of the activities as outlined in the manufacturing and clinical work plan are incurred by installment as outlined in the agreement with the foundations. As a result, we record foundation revenues to match the costs of the activities by installment performed under the collaborative agreement.

We recorded royalty revenue for MuGard of $0 in the first quarter of 2019 and $0.1 million in the first quarter of 2018. We licensed MuGard to AMAG Pharmaceuticals, Inc. (“AMAG”) and Norgine B.V. (“Norgine”).

Total research and development spending for the first quarter of 2019 was $11.7 million, as compared to $8.2 million for the same period of 2018, an increase of $3.5 million. The increase in expenses was primarily due to:

increased clinical and development work for EB-101, ABO-102, ABO-101 and other gene therapy products ($1.8 million); and

increased salary and related costs ($1.7 million) from the hiring of additional scientific staff.

Total general and administrative expenses were $5.7 million for the first quarter of 2019, as compared to $2.9 million for the same period of 2018, an increase of $2.8 million. The increase in expenses was primarily due to:

increased salary and related costs ($0.9 million);

increased professional fees ($1.0 million);

increased office rent costs ($0.5 million); and

increases in net other general and administrative expenses ($0.4 million).

Depreciation and amortization were $1.7 million for the first quarter of 2019, as compared to $0.2 million for the same period in 2018, an increase of $1.5 million. The increase was driven primarily by increased amortization expense resulting from the REGENXBIO license, which we entered into in November 2018.

Net loss for the first quarter of 2019 was $18.6 million, or a $0.39 basic and diluted loss per common share as compared to a net loss of $10.5 million, or a $0.22 basic and diluted loss per common share, for the same period in 2018.

LIQUIDITY AND CAPITAL RESOURCES

We have historically funded our operations primarily through sales of common stock and, to a significantly lesser extent, foundation grants and licensing agreements. Our principal source of liquidity is cash, cash equivalents and short-term investments. As of March 31, 2019 and December 31, 2018, our cash, cash equivalents and short-term investments were $68.3 million and $85.0 million, respectively.

As of March 31, 2019 and December 31, 2018, our working capital was $50.3 million and $68.5 million, respectively. The decrease in working capital at March 31, 2019 resulted primarily from $15.1 million of cash used for operating activities and $1.2 million for capital expenditures during the three months ended March 31, 2019.

On August 17, 2018, we entered into an open market sale agreement with Jefferies LLC. Pursuant to the terms of this agreement, we may sell from time to time, through Jefferies LLC, shares of our common stock for an aggregate sales price of up to $150 million. Any sales of shares pursuant to this agreement will be made under our effective “shelf” registration statement on Form S-3 that is on file with and has been declared effective by the SEC. We did not sell any shares of our common stock under this agreement during the three months ended March 31, 2019.

On October 16, 2017, we announced a collaborative agreement between us and nine Sanfilippo foundations to provide up to approximately $13.9 million of grants to us in installments for the advancement of our clinical stage gene therapies for MPS IIIA and MPS IIIB, subject to the achievement of certain milestones. As of March 31, 2019, we had received $5.7 million of such grants. We did not receive any cash from such grants during the three months ended March 31, 2019.

Since our inception, we have incurred negative cash flows from operations and have expended, and expect to continue to expend, substantial funds to complete our planned product development efforts. Since inception, our expenses have significantly exceeded revenues, resulting in an accumulated deficit of $429 million as of March 31, 2019. We have not been profitable since inception and to date have received limited revenues from the sale of products. We expect to incur losses for the next several years as we continue to invest in product research and development, preclinical studies, clinical trials and regulatory compliance and cannot provide assurance that we will ever be able to generate sufficient product sales or royalty revenue to achieve profitability on a sustained basis, or at all.

If we raise additional funds by selling additional equity securities, the relative equity ownership of our existing investors will be diluted and the new investors could obtain terms more favorable than previous investors. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.

We plan to expend substantial funds to conduct research and development programs, expand our manufacturing capabilities and conduct preclinical studies and clinical trials of potential products, including research and development with respect to our acquired and developed technology. Our future capital requirements and adequacy of available funds will depend on many factors, including:

the successful development and commercialization of our gene and cell therapy and other product candidates;

the ability to establish and maintain collaborative arrangements with corporate partners for the research, development and commercialization of products;

continued scientific progress in our research and development programs;

the magnitude, scope and results of preclinical testing and clinical trials;

the costs involved in filing, prosecuting and enforcing patent claims;

the costs involved in conducting clinical trials;

competing technological developments;

the cost of manufacturing and scale-up;

the ability to establish and maintain effective commercialization arrangements and activities; and

successful regulatory filings.

Due to uncertainties and certain risks described in our most recent Form 10-K, including those relating to our ability to successfully commercialize our product candidates, our ability to obtain necessary additional capital to fund operations in the future, our ability to successfully manufacture our products and our product candidates in clinical quantities or for commercial purposes, government regulation to which we are subject, the uncertainty associated with preclinical and clinical testing, intense competition that we face, market acceptance of our products, the potential necessity of licensing technology from third parties and protection of our intellectual property, it is not possible to reliably predict future spending or time to completion by project or product category or the period in which material net cash inflows from significant projects are expected to commence. If we are unable to timely complete a particular project, our research and development efforts could be delayed or reduced, our business could suffer depending on the significance of the project and we might need to raise additional capital to fund operations, as discussed in the risk factors in our most recent Form 10-K, including those relating to the uncertainty of the success of our research and development activities and our ability to obtain necessary additional capital to fund operations in the future. As discussed in such risk factors, delays in our research and development efforts and any inability to raise additional funds could cause us to eliminate one or more of our research and development programs.

We plan to continue our policy of investing any available funds in certificates of deposit, money market funds, government securities and investment-grade, interest-bearing securities. We do not invest in derivative financial instruments.

OFF-BALANCE SHEET ARRANGEMENTS

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our business and financial results are not materially affected by fluctuations in currency exchange rates or interest rates. We do not use derivative financial instruments for trading or speculative purposes.

Interest Rate Risk

Our exposure to market risk for changes in interest rates relates to our investment portfolio. Our investment strategy is focused on preserving capital and supporting our liquidity requirements, while earning a reasonable market return. We invest only in U.S. government, U.S. agency and U.S. treasury securities. The market value of our investments would not materially decline if current market interest rates rise given the short duration of our investments.

Concentrations of Risk

We invest excess cash in short-term, fixed-rate debt securities, and diversify the investments between financial institutions.

Foreign Currency Fluctuation Risk

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may continue to contract with foreign vendors that are located in Europe and Australia.

Inflation Fluctuation Risk

Inflation can affect us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the first quarter of 2019 or 2018.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management and consultants, including the Executive Chairman (our principal executive officer) and Chief Financial Officer (our principal financial officer), we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls and Procedures”), as of March 31, 2019, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Conclusion of Evaluation — Based on this Disclosure Controls and Procedures evaluation, the Executive Chairman and Chief Financial Officer concluded that our Disclosure Controls and Procedures as of March 31, 2019 were effective.

Changes in Internal Control Over Financial Reporting – There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2019 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

PART II -- OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

ITEM 1A.

RISK FACTORS.

Our business and financial results are subject to numerous risks and uncertainties. As a result, the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our Form 10-K for the year ended December 31, 2018 should be carefully considered. There have been no material changes in the assessment of our risk factors from those set forth in our 2018 Form 10-K.

ITEM 6.

EXHIBITS.

See Exhibit Index below, which is incorporated by reference herein.

Exhibit Index

Exhibits:
3.1		Restated Certificate of Incorporation of Abeona Therapeutics Inc.

3.2		Amended and Restated Bylaws of Abeona Therapeutics Inc. (incorporated by reference to our Form 10-K filed on March 18, 2019)

10.1+		Offer Letter, dated January 8, 2019, by and between Abeona Therapeutics Inc. and Christine Berni Silverstein (incorporated by reference to our Form 8-K filed on January 10, 2019)

10.2+		Offer Letter, dated January 8, 2019, by and between Abeona Therapeutics Inc. and João Siffert, M.D. (incorporated by reference to our Form 8-K filed on February 13, 2019)

31.1		Principal Executive Officer Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

31.2		Principal Financial Officer Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

32*		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101		The following materials from Abeona’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018, (ii) Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018, (iii) Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2019 and 2018, (iv) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018, and (v) Notes to Condensed Consolidated Financial Statements.

* Pursuant to Item 601(b)(32)(ii) of Regulation S-K, this exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filing.

+ Management contract or compensation plans or arrangements in which directors or executive officers are eligible to participate.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ABEONA THERAPEUTICS INC.

Date:	May 10, 2019	By:	/s/ Steven H. Rouhandeh
			Steven H. Rouhandeh
			Executive Chairman
			(Principal Executive Officer)

Date:	May 10, 2019	By:	/s/ Christine Silverstein
			Christine Silverstein
			Chief Financial Officer
			(Principal Financial Officer)

EX-3.1 2 tv520699_ex3-1.htm EXHIBIT 3.1

Exhibit 3.1

RESTATED

CERTIFICATE OF INCORPORATION
OF
Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:

1. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on June 22, 1989 (the “Original Certificate”), and the original name of the corporation was Chemex-Delaware, Inc.

2. Pursuant to Section 245 of the General Corporation Law of the State of Delaware (the “DGCL”), this Restated Certificate of Incorporation restates and integrates the provisions of the Original Certificate of the Corporation, as previously amended or supplemented.

3. This Restated Certificate of Incorporation does not amend the provisions of the Corporation’s Original Certificate, as previously amended or supplemented, and there is no discrepancy between the provisions in this Restated Certificate of Incorporation and the provisions in the Corporation’s Original Restated Certificate, as previously amended or supplemented.

4. This Restated Certificate of Incorporation has been duly approved by the Board of Directors of the Corporation in accordance with Sections 245 of the DGCL.

Article I.

The name of the Corporation is:
Abeona Therapeutics Inc.

Article II.

A. The address of the initial registered office of the Corporation is 1209 Orange Street, County of New Castle, Wilmington, Delaware 19801.

B. The name of the initial registered agent for the Corporation at such address is the Corporation Trust Company.

Article III.

The nature of the business of the Corporation and the objects and purposes to be transacted, promoted, and carried on by it are to generally engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of Delaware.

Article IV.

This Corporation shall have perpetual existence, which existence shall commence upon the filing by the Secretary of State of Delaware of this Certificate of Incorporation.

Article V.

A. The aggregate number of shares of Common Stock which the Corporation shall have authority to issue is Two Hundred Million (200,000,000) shares with a par value of one cent ($0.01) per share.

B. The aggregate number of shares of preferred stock which the Corporation shall have authority to issue is Two Million (2,000,000) shares with a par value of one cent ($0.01) per share in one or more series. Each series of preferred stock shall be designated by the board of directors so as to distinguish the shares thereof and the shares of all other series and classes. The board of directors may, by resolution, from time to time divide shares of the preferred stock into series and fix and determine the number of shares and the relative rights and preferences of any series so established, which relative rights and preferences of any series so established may be greater or lesser than those granted to the common stock as provided herein. Notwithstanding the foregoing, all shares of preferred stock shall be identical, except as to the following relative rights and preferences, in respect of any or all of which there may be variations between different series, namely the rate of dividends (including the date from which dividends shall be cumulative), the price at, and the terms and conditions on which, shares may be redeemed, the amounts payable on shares in the event of voluntary or involuntary liquidation or dissolution, sinking fund provisions for the redemption or purchase of shares in the event shares of any series or issue with sinking fund provisions, and the terms and conditions on which shares of any series may be converted in the event shares of any series are issued a privilege of conversion. Each share of any series of preferred stock shall be identical with all the shares of such series. The consideration for the issuance of shares may be paid in whole or in part in money and other property, tangible or intangible, or in labor or in services actually performed for the Corporation. When payment of the consideration for which shares are to be issued has been received or, when payment of the capital consideration has been received and the Corporation has received a binding obligation from the purchaser to pay the balance of the purchase price; such shares shall be deemed to be fully paid and not liable for any further call or assessment thereon.

C. Each stockholder of record of the common stock shall have one vote for each share of stock standing in his name on the books of the Corporation and entitled to vote. In the election of directors, cumulative voting shall be allowed. The voting rights, if any, of the shareholders of any series, if any, of preferred stock, shall be designated, by resolution, of the board of directors.

D. Stockholders of the common or preferred stock, regardless of the series of the preferred stock shall not have the preemptive right to acquire unissued or treasury shares or securities convertible into such shares or carrying a right to subscribe to or acquire shares. Such provision shall apply to both shares outstanding and to newly issued shares.

Article VI.

A. Any purchase or other acquisition, directly or indirectly, in one or more transactions, by the Corporation of any shares of the Corporation’s Voting Stock or any Voting Stock Right known by the Corporation to be beneficially owned by any Interested Shareholder who has beneficially owned such security or right for less than two years prior to the date of such purchase shall, except as hereinafter expressly provided, require the affirmative vote of the holders of not less than 66 2/3% of all shares entitled to vote. Such affirmative vote shall be required notwithstanding the fact that no vote may be required, or that a lesser percentage may be specified, by law or any agreement with any national securities exchange, or otherwise, but no such affirmative vote shall be required with respect to any purchase or other acquisition by the Corporation of Voting Stock or Voting Stock Right purchased at or below Fair Market Value or made as part of a tender or exchange offer made on the same terms to all holders of such securities and complying with the applicable requirements of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules and regulations thereunder or in a Public Transaction.

B. A majority of the Board of Directors shall have the power and duty to determine for the purposes of this Article VI, on the basis of information known to it after reasonable inquiry, all facts necessary to determine compliance with this Article VI, including without limitation: (i) if (1) a person is an Interested Shareholder; (2) any Voting Stock and Voting Stock Right is beneficially owned by any person; (3) a person is an Affiliate or Associate of another; (4) a transaction is a Public Transaction; and (ii) the Fair Market Value of any Voting Stock or Voting Stock Right.

C. For the purposes of this Article VI, the following terms shall mean:

(i) An “Affiliate” of, or a person “Affiliated” with, a specified person, is a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the person specified.

(ii) The term “Associate” used to indicate a relationship with any person, means: (1) any corporation or organization (other than the Corporation or a Subsidiary of the Corporation) of which such person is an officer, director or partner or is, directly or indirectly, the beneficial owner of 20% or more of any class of voting stock; (2) any trust or other estate in which such person has at least a 20% beneficial interest or as to which such person serves as trustee or in a similar fiduciary capacity; and (3) any relative or spouse of such person, or any relative of such spouse, who has the same residence as such person.

(iii) A person shall “beneficially own” any Voting Stock or Voting Stock Right: (1) which such person or any of its Affiliates or Associates beneficially owns, directly or indirectly; (2) which such person or any of its Affiliates or Associates has (a) the right to acquire (whether such right is exercisable immediately or only after the passage of time), pursuant to any agreement, arrangement or understanding or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise, or (b) any right to vote pursuant to any agreement, arrangement or understanding; or (3) which is beneficially owned, directly or indirectly, by any other person with which such person or any of its Affiliates or Associates has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting or disposing of any security of any class of the Corporation or any of its Subsidiaries. For the purposes of determining whether a person is an Interested Shareholder, the relevant class of securities outstanding shall be deemed to include all such securities of which such person is deemed to be the “beneficial owner” through application of this subparagraph (iii), but shall not include any other securities of such class which may be issuable pursuant to any agreement, arrangement or understanding, or upon exercise of conversion rights, warrants or options, or otherwise, but are not yet issued.

(iv) “Fair Market Value” means, for any share of Voting Stock or any Voting Stock Right, the average of the closing sale prices during the 90-day period immediately preceding the repurchase of such Voting Stock or any Voting Stock Right, as the case may be, on the Composite Tape for New York Stock Exchange-Listed Stocks, or, if such Voting Stock or any Voting Stock Right is not quoted on the Composite Tape, on the New York Stock Exchange, or, if such Voting Stock or any Voting Stock Right, is not listed on such Exchange, on the principal United States securities exchange registered under the Exchange Act on which such Voting Stock or any Voting Stock Right is listed, or if such Voting Stock or any Voting Stock Right is not listed on any such exchange, the average of the closing bid quotations with respect to a share of such Voting Stock or any Voting Stock Right during the 90-day period immediately preceding the date in question of a share of such Voting Stock or any Voting Stock Right quoted by a registered national securities association, or if none of the preceding shall be applicable as determined by the Board of Directors in good faith.

(v) “Interested Shareholder” shall mean any person or group of persons (other than (1) the Corporation, (2) any of its Subsidiaries, (3) any benefit plan or trust of or for the benefit of the Corporation or any of its Subsidiaries, or (4) any trustee, agent or other representative of any of the foregoing) who or which is the beneficial owner, directly or indirectly, of more than 5% of any class of Voting Stock or any Voting Stock Rights.

(vi) A “Public Transaction” shall mean any (1) purchase of shares offered pursuant to an effective registration statement under the Securities Act of 1933, as amended (2) open market purchases of shares if, in either such case, the price and other terms of sale are not negotiated by the purchaser and seller of the beneficial interest in the shares.

(vii) The term “Voting Stock” shall mean stock of any class or series of the Corporation entitled to vote generally in the election of directors.

(viii) The term “Voting Stock Right” shall mean any security convertible into, and any warrant, option or other right of any kind to acquire beneficial ownership of, any Voting Stock, other than securities issued pursuant to any of the Corporation’s employee benefit plans.

D. Notwithstanding anything contained in this Certificate to the contrary, the affirmative vote of the holders of at least 66 2/3% of the shares entitled to vote shall be required to alter, amend, repeal or to adopt any provision inconsistent with this Article VI.

Article VII.

A. The number of persons constituting the board of directors of the Corporation shall be fixed by the Bylaws of the Corporation. Directors need not be residents of the State of Delaware or stockholders of the Corporation and shall exercise all the powers conferred on the Corporation by this Certificate of Incorporation and by the laws of the State of Delaware. The initial board of directors shall consist of nine (9) members. The use of a written ballot in connection with the election of directors shall not be required.

B. The board of directors shall be divided into three classes as nearly equal in number as possible. At each Annual Meeting of Stockholders the directors whose terms expire shall be elected for a term of office to expire at the third succeeding Annual Meeting of Stockholders.

C. Nominations for the election of directors may be made by the board of directors or by any record owner of capital stock of the Corporation entitled to vote in the election of directors. However, a stockholder may nominate one or more persons for election as a director at a meeting, only if written notice of such stockholder’s intent to make such nomination or nominations has been given, either by personal delivery or by United States mail, postage prepaid, to the Secretary of the Corporation not later than: (i) with respect to an election to be held at an annual meeting of stockholders, one hundred twenty (120) days in advance of such meeting; and (ii) with respect to an election to be held at a special meeting of stockholders for the election of directors, the close of business on the seventh day following the earlier of: (1) the date on which notice of such meeting is first given to stockholders; and (2) the date on which a public announcement of such meeting is first made. Each notice shall include: (i) the name and address of each stockholder of record who intends to appear in person or by proxy to make the nomination and of the person or persons to be nominated; (ii) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are made by the stockholder; (iii) such other information regarding each nominee proposed by such stockholder as would have been required to be included in a proxy statement filed pursuant to the proxy rules of the Securities and Exchange Commission; and (iv) the consent of each nominee to serve as a director of the Corporation if so elected. The chairman of the meeting may refuse to acknowledge the nomination of any person not made in compliance with the foregoing procedure.

D. Any director, or the entire board of directors, may be removed from office at any time, but only for cause and only upon the affirmative vote of the holders of at least 66 2/3% of the shares entitled to vote in the election of directors.

E. Notwithstanding any other provisions of this Certificate of Incorporation or the Bylaws of the Corporation, the affirmative vote of the holders of at least 66 2/3% of the shares entitled to vote shall be required to amend, repeal, or adopt any provisions inconsistent with this Article VII.

Article VIII.

No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers have any interest, shall be void or voidable solely for that reason or solely because the director or officer is present at or participates in the meeting of the board or committee thereof which authorizes, approves, or ratifies the contract or transaction or solely because his or their votes are counted for such purpose if: (i) The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the board of directors or the committee, and the board or committee in good faith authorizes, approves, or ratifies the contract or transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors are less than a quorum; (ii) The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically authorized, approved, or ratified in good faith by vote of the stockholders; or (iii) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved, or ratified by the board of directors, a committee thereof, or the stockholders.

Common or interested directors may be counted in determining the presence of a quorum at a meeting of the board of directors or a committee thereof which authorizes, approves, or ratifies such contract or transaction.

Article IX.

The officers of the Corporation shall be subject to the doctrine of corporate opportunities only insofar as it applies to business opportunities in which this Corporation has expressed an interest as determined from time to time by the Corporation’s board of directors, as evidenced by resolutions appearing in its minutes. When so delineated, opportunities within such areas of interest shall be disclosed promptly to the board of directors. Until such time as this Corporation, through its board of directors, has designated an area of interest, the officers shall be free to engage in such areas and to continue a business existing prior to the time that such an area of interest has been designated.

Article X.

A. The Corporation shall indemnify all persons to the extent and in the manner permitted by the provisions of the General Corporation Law of Delaware, as amended from time to time, subject to any permissible expansion or limitation of such indemnification as may be set forth in the Bylaws of the Corporation or any stockholders’ or directors’ resolution or by contract. The provisions of this Article shall also be applicable to the personal representative and heirs of all persons who may be indemnified pursuant to the General Corporation Law of Delaware.

B. No director of the Corporation shall be liable to the Corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except for liability for: (i) any breach of the director’s duty of loyalty to the Corporation or its stockholders; (ii) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) unlawful payment of dividends or unlawful repurchases or redemptions as more fully described in Section 174 of the General Corporation Law of Delaware; or (iv) any transaction from which the directors derived an improper personal benefit. If the General Corporation Law of Delaware is amended after the filing of this Certificate of Incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of Delaware. Any repeal or modification of the foregoing by the shareholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or modification.

C. Notwithstanding any other provision of this Certificate of Incorporation, the affirmative vote of at least 66 2/3% of the shares entitled to vote shall be required to alter, amend, repeal or adopt any provision inconsistent with this Article X.

Article XI.

The Corporation shall be entitled to treat the registered holder of any shares of the Corporation as the owner thereof for all purposes, including all rights derived from such shares, and shall not be bound to recognize any equitable or other claim to or interest in such shares or rights deriving from such shares, on the part of any other persons, including but without limiting the generality thereof, a purchaser, assignee or transferee of such shares or rights deriving from such shares, unless and until such purchaser, assignee or transferee or other person becomes a registered holder of such shares, whether or not the Corporation shall have either actual or constructive notice of the interest of such purchaser, assignee, transferee, or any other person. The purchaser, assignee, or transferee of any of the shares of the Corporation shall not be entitled: (i) To receive notice of the meetings of the stockholders; (ii) To vote at such meetings; (iii) To examine a list of the stockholders; (iv) To be paid dividends or other sums payable to stockholders; or (v) To own, enjoy, and exercise any other privilege or right derived from such shares against the Corporation, until such purchaser, assignee, or transferee has become the registered holder of such shares.

Article XII.

A. The Corporation’s Bylaws may contain any provisions for the regulation and management of the affairs of the Corporation not inconsistent with the laws of Delaware or this Certificate of Incorporation. In furtherance and not in limitation of the powers conferred by statute, the board of directors is expressly authorized to adopt, amend or repeal the Bylaws of the Corporation. Notwithstanding the foregoing or any other provisions of this Certificate of Incorporation, and except as otherwise provided by law, the Bylaws may be altered, amended or repealed by the affirmative vote of the holders of at least 66 2/3% of the shares entitled to vote.

B. Notwithstanding any other provision of this Certificate of Incorporation, the affirmative vote of at least 66 2/3% of the shares entitled to vote shall be required to alter, amend, repeal or adopt any provision inconsistent with this Article XII.

Article XIII.

The right is expressly reserved to amend, alter, change or repeal any provision or provisions contained in this Certificate of Incorporation or any Article herein in any manner or respect now or hereafter permitted or provided by the General Corporation Law of Delaware or by this Certificate of Incorporation, and the rights of all officers, directors and stockholders are expressly made subject to such reservation.

EX-31.1 3 tv520699_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C.

SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Steven H. Rouhandeh, certify that:

I have reviewed this report on Form 10-Q of Abeona Therapeutics Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 10, 2019	By:	/s/ Steven H. Rouhandeh
			Steven H. Rouhandeh
			Executive Chairman
			(Principal Executive Officer)

EX-31.2 4 tv520699_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C.

SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Christine Silverstein, certify that:

I have reviewed this report on Form 10-Q of Abeona Therapeutics Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 10, 2019	By:	/s/ Christine Silverstein
			Christine Silverstein
			Chief Financial Officer
			(Principal Financial Officer)

EX-32 5 tv520699_ex32.htm EXHIBIT 32

EXHIBIT 32

CERTIFICATION PURSUANT TO 18 U.S.C.

SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Abeona Therapeutics Inc. (the "Company") on Form 10-Q for the three months ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Steven H. Rouhandeh, Executive Chairman of the Company, and Christine Silverstein, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	May 10, 2019	By:	/s/ Steven H. Rouhandeh
			Steven H. Rouhandeh
			Executive Chairman
			(Principal Executive Officer)

Date:	May 10, 2019	By:	/s/ Christine Silverstein
			Christine Silverstein
			Chief Financial Officer
			(Principal Financial Officer)

EX-101.INS 6 abeo-20190331.xml XBRL INSTANCE DOCUMENT 0000318306 2019-01-01 2019-03-31 0000318306 2019-03-31 0000318306 2018-12-31 0000318306 2018-01-01 2018-03-31 0000318306 2019-05-06 0000318306 2018-03-31 0000318306 2018-04-01 2018-06-30 0000318306 2017-12-31 0000318306 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000318306 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000318306 us-gaap:GrantMember 2019-01-01 2019-03-31 0000318306 us-gaap:RoyaltyMember 2019-01-01 2019-03-31 0000318306 abeo:AbeonaTherapeuticsLlcMember 2019-01-01 2019-03-31 0000318306 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000318306 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000318306 abeo:DollarFiveWarrantMember 2019-01-01 2019-03-31 0000318306 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000318306 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000318306 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000318306 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000318306 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000318306 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000318306 us-gaap:WarrantMember 2019-01-01 2019-03-31 0000318306 abeo:DollarFiveWarrantMember 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel1Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel3Member 2019-03-31 0000318306 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-31 0000318306 us-gaap:GoodwillMember us-gaap:FairValueMeasurementsNonrecurringMember 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:GoodwillMember us-gaap:FairValueInputsLevel1Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:GoodwillMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:GoodwillMember us-gaap:FairValueInputsLevel3Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-03-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FiniteLivedIntangibleAssetsMember 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:GoodwillMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:GoodwillMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:GoodwillMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000318306 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:GoodwillMember 2018-12-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0000318306 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0000318306 us-gaap:GrantMember 2018-01-01 2018-03-31 0000318306 us-gaap:RoyaltyMember 2018-01-01 2018-03-31 0000318306 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000318306 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000318306 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000318306 abeo:DollarFiveWarrantMember 2018-01-01 2018-03-31 0000318306 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000318306 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000318306 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000318306 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0000318306 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0000318306 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0000318306 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000318306 us-gaap:WarrantMember 2018-01-01 2018-03-31 0000318306 abeo:REGENXBIOMember us-gaap:LicensingAgreementsMember 2018-10-15 2018-11-04 0000318306 abeo:REGENXBIOMember us-gaap:LicensingAgreementsMember 2018-11-04 0000318306 abeo:DollarFiveWarrantMember 2018-03-31 0000318306 us-gaap:CommonStockMember 2018-12-31 0000318306 us-gaap:CommonStockMember 2019-03-31 0000318306 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000318306 us-gaap:RetainedEarningsMember 2018-12-31 0000318306 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000318306 us-gaap:RetainedEarningsMember 2019-03-31 0000318306 us-gaap:CommonStockMember 2017-12-31 0000318306 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000318306 us-gaap:RetainedEarningsMember 2017-12-31 0000318306 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000318306 us-gaap:RetainedEarningsMember 2018-03-31 0000318306 us-gaap:CommonStockMember 2018-03-31

25924000

18750000

38000

81000

3372000

3802000

71721000

88851000

10356000

9443000

32466000

1147000 597000

166136000

174399000

4189000

6122000

10000000 10000000

21416000

20354000

48343000

40354000

479000

546057000

543754000

-428743000

-410188000

117793000

134045000

166136000

174399000

20000000

P20Y

44859000

3162000

1817000

41697000

43042000

4033000

5378000

16152000

41697000

1345000

87000

41697000

42387000

66218000

11737000

8162000

5659000

2878000

1658000

174000

19054000

11214000

-19054000

-10683000

499000

156000

0 3000

-18555000

-10530000

-0.39

-0.22

47948421

47060523

-18555000

-10530000

-43000

-15078000

-4082000

1226000

3502000

22774000

-3502000

-430000

-643000

28000

1829000

144000

28000

1685000

2103000

1900000

172000 172000

32466000

43042000

32466000

5241000

3936000

20000000 20000000

481000

50000

531000

24000000

3000

169000

7724000

-5755000

19310000

138030000

27034000

132275000

25924000

131995000

1110000

280000

27034000 132275000

68300000

10000000 60000000

42387000

479000

543754000

-410188000

134045000

2103000

172000

28000

-18555000

479000

546057000

-428743000

47944486

5208

47949694

469000

3000

472000

529421000

-359792000

6275000

1900000

172000

1682000

0 0

-10530000

533319000

-364047000

170098000

6275000

1900000

172000

1685000

-10530000

169744000

46888108

267196

48762

47232940

0.01

200000000

47949694

47944486

47949694

47944486

5.00

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 5 – FAIR VALUE MEASUREMENTS</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of receivables, prepaid expenses, other assets, accounts payable, accrued expenses, payable to licensor and deferred revenue approximate their carrying amounts due to the relatively short maturity of these instruments.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: symbol; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 1 – Quoted prices in active markets for identical assets or liabilities.</div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: symbol; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: symbol; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of March 31, 2019 and December 31, 2018 are summarized below:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 95%;"><tr><td style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total </div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains/(Losses)</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 35.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">42,387,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">42,387,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">     -</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Non-recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Licensed technology, net</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">41,697,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">41,697,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 95%;"><tr><td style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total </div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains/(Losses)</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 35.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">66,218,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">66,218,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">     -</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Non-recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Licensed technology, net</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">43,042,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">43,042,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

42387000

66218000

100000000 10000000

66218000

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of March 31, 2019 and December 31, 2018 are summarized below:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 95%;"><tr><td style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total </div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains/(Losses)</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 35.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">42,387,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">42,387,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">     -</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Non-recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Licensed technology, net</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">41,697,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">41,697,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.25in;width: 95%;"><tr><td style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total </div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains/(Losses)</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 35.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">66,218,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">66,218,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">     -</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Non-recurring</div></div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Licensed technology, net</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">43,042,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">43,042,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">32,466,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

8900000

289000

73000

47000

1266000

1699000

1713000

1727000

1741000

3667000

11813000

3196000

8617000

P82M

1690000

6927000

0.096

1.09

0.0246

0.0237

0.0

P5Y

1032000

1056000

1071000

844000

2103000

1900000

172000

8749000

6927000

1690000

296000

150000 0 910000 -3516000

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 6 – STOCK-BASED COMPENSATION</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes stock-based option compensation for the three months ended March 31, 2019 and 2018:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the three months ended March 31,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,032,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,056,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,071,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">844,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense included in operating expense</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,103,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,900,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,103,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,900,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Tax benefit</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense, net of tax</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,103,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,900,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: symbol; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility – we estimate the volatility of our share price at the date of grant using a “look-back” period which coincided with the expected term, defined below. We believe using a “look-back” period which coincides with the expected term is the most appropriate measure for determining expected volatility.</div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: symbol; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term – we estimate the expected term using the “simplified” method, as outlined in Staff Accounting Bulletin No. 107, “Share-Based Payment.”</div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: symbol; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate – we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term of the options in effect at the time of grant.</div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: symbol; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividends – we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare a dividend.</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the three months ended March 31,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">109</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0pt; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">109</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0pt; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">5</div> years</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">5</div> years</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.46</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.37</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended March 31, 2019, we granted 201,000 stock options and the weighted-average fair value was $5.29 and the weighted-average exercise price was $6.69. For the three months ended March 31, 2018, we granted 645,000 stock options and the weighted-average fair value was $10.83 and the weighted-average exercise price was $13.72.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes restricted common stock compensation expense for the three months ended March 31, 2019 and 2018:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the three months ended March 31,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 74.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense included in operating expense</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Tax benefit</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense, net of tax</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">172,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We did not grant any common stock to directors or employees during the three months ended March 31, 2019 and 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

201000

5.29

6.69

645000

10.83

13.72

5696353

1820686

5807531

2838576

2067000

543000

0.01

0.04

10-Q false 2019-03-31 2019 Q1 ABEONA THERAPEUTICS INC. 0000318306 --12-31 Accelerated Filer ABEO 49162047 false true

2103000

1900000

2103000

1900000

172000

28874 0 144000 0 144000 20000000 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares

EX-101.SCH 7 abeo-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - NEW ACCOUNTING STANDARD IMPLEMENTED link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - SHORT-TERM INVESTMENTS link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - LICENSED TECHNOLOGY link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - OPERATING LEASES link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - SHORT-TERM INVESTMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - LICENSED TECHNOLOGY (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - OPERATING LEASES (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - NEW ACCOUNTING STANDARD IMPLEMENTED (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - SHORT-TERM INVESTMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - LICENSED TECHNOLOGY (Details) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - LICENSED TECHNOLOGY (Details 1) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - LICENSED TECHNOLOGY (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - OPERATING LEASES (Details) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - OPERATING LEASES (Details 1) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 abeo-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 abeo-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 abeo-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Small Business Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Receivables, Net, Current Receivables Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Short-term Investments Short-term investments Property, Plant and Equipment, Net Property and equipment, net Finite-Lived Intangible Assets, Net Licensed technology, net Total Goodwill Goodwill Other Assets and Restricted Cash Other assets and restricted cash Amount of assets classified as other and amount of cash restricted as to withdrawal or usage. Assets Total assets Finance Lease, Right-of-Use Asset Right-of-use lease assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Payable Due Licensor Current Current portion of payable to licensor The amount payable due to licensor. Deferred Revenue, Current Deferred revenue Liabilities, Current Total current liabilities Accrued Liabilities, Current Accrued expenses Finance Lease, Liability, Current Current portion of lease liability Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock - $0.01 par value; authorized 200,000,000 shares; issued and outstanding 47,949,694 at March 31, 2019; issued and outstanding 47,944,486 at December 31, 2018 Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Balance Balance Liabilities and Equity Total liabilities and stockholders' equity Payable Due Licensor Non current Payable to licensor, net of current portion Amount less current portion of payable due to licensor. Finance Lease, Liability, Noncurrent Long-term lease liabilities Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Revenues [Abstract] Revenues: Revenues Total revenues Costs and Expenses [Abstract] Expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Depreciation, Depletion and Amortization Depreciation and amortization Costs and Expenses Total expenses Operating Income (Loss) Loss from operations Investment Income, Nonoperating Interest and miscellaneous income Interest And Other Expense Interest and other expense Interest and other expenses associated with non operating financing activities of the entity. Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Earnings Per Share, Basic and Diluted Basic and diluted loss per common share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding – basic and diluted Product and Service [Axis] Product and Service [Domain] Grant [Member] Foundation revenues [Member] Royalty [Member] Royalties [Member] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated deficit [Member] Title of Individual [Axis] Relationship to Entity [Domain] Sale of Stock [Axis] Sale of Stock [Domain] Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period Value Warrants Exercised Exercise of $5.00 warrants Value of stock issued as a result of the exercise of warrants. Stock Issued During Period Shares Warrants Exercised Exercise of $5.00 warrants (in shares) Number of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Stock Options Exercised Common stock issued for cash exercise of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Common stock issued for cash exercise of options (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Cumulative Effect on Retained Earnings, Net of Tax Cumulative effect adjustment of ASC 606 on January 1, 2018 Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued cashless warrant exercises (in shares) Non cash Or Part Non cash Acquisition Non cash Financial Or Equity Instrument Consideration Value Of Warrants Issued1 cashless warrant exercises Value of Cashless Warrants Issued Stock Issued During Period, Value, Share-based Compensation, Gross Restricted stock-based compensation expense Statement of Stockholders' Equity [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Dollar Five Warrant [Member] Award Type [Axis] Equity Award [Domain] Class of Warrant or Right, Exercise Price of Warrants or Rights Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to cash used in operating activities: Allocated Share-based Compensation Expense Stock-based compensation expense Stock-based compensation expense included in operating expense Total stock-based compensation expense Allocated Share Based Compensation Expense Restricted Stock Restricted stock-based compensation expense Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, restricted shares of stock, restricted unit, restricted stock options or other restricted equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) in Receivables Receivables Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase Decrease Right Of Use Assets And Other Assets Right-of-use lease assets and other assets Represents increase or decrease in right of use assets Increase Decrease In Accounts Payable And Accrued And Lease Liabilities Accounts payable, accrued expenses and lease liabilities Increase decrease in accrued expenses and lease liabilities. Other Noncash Income Non-cash earnings on investments Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Capital expenditures Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of short-term investments Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Stock Options Exercised Proceeds from exercise of stock options Proceeds from Warrant Exercises Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Supplemental Cash Flow Information [Abstract] Supplemental cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Restricted Cash and Cash Equivalents Restricted cash Cash And Cash Equivalents Restricted Cash Total cash, cash equivalents and restricted cash Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES Accounting Changes and Error Corrections [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] NEW ACCOUNTING STANDARD IMPLEMENTED Investments, Debt and Equity Securities [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] SHORT-TERM INVESTMENTS Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] LICENSED TECHNOLOGY Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION Leases [Abstract] Leases of Lessee Disclosure [Text Block] OPERATING LEASES Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Nature Of Operations [Policy Text Block] Background Disclosure of accounting policy for business description. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Uses and Sources of Liquidity Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation Debt Securities, Available-for-sale [Table Text Block] Schedule of available-for-sale investments held Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of licensed technology Finite-lived Intangible Assets Amortization Expense [Table Text Block] Amortization expense for intangible assets Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Financial assets and liabilities measured at fair value on recurring basis Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions to estimate the fair value of the options granted Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summarization of stock-based compensation Employee Stock Option [Member] Stock Options [Member] Restricted Stock [Member] Lease, Cost [Table Text Block] Components of lease cost Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block] Schedule Of Supplemental Cash Flow Information Related To Leases Schedule of supplemental cash flow information related to leases Range [Axis] Range [Domain] Cash, Cash Equivalents, and Short-term Investments Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Operating Results New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Operating Results New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Diluted Earnings Per Share New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Diluted Earnings Per Share Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Operating Lease, Liability Total operating lease liabilities Total operating lease liabilities Operating Lease, Right-of-Use Asset Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Debt Securities, Available-for-sale Finite-Lived Intangible Assets, Gross Licensed technology Finite-Lived Intangible Assets, Accumulated Amortization Less accumulated amortization Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2023 Finite-Lived Intangible Assets, Amortization Expense, after Year Five Thereafter Legal Entity [Axis] Entity [Domain] REGENXBIO [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Abeona Therapeutics LLC [Member] Finite-Lived Intangible Asset, Useful Life Amortization of Intangible Assets EX-101.PRE 11 abeo-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 tv520699_img1.jpg GRAPHIC begin 644 tv520699_img1.jpg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ⅅ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®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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2019

May 06, 2019

Document and Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q1

Entity Registrant Name ABEONA THERAPEUTICS INC.

Entity Central Index Key 0000318306

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Trading Symbol ABEO

Entity Common Stock, Shares Outstanding 49,162,047

Entity Emerging Growth Company false

Entity Small Business true

X

- Definition
Document and Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: abeo_DocumentAndEntityInformationAbstract

Namespace Prefix: abeo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Balance Sheets - USD ($)

Mar. 31, 2019

Dec. 31, 2018

Current assets:

Cash and cash equivalents $ 25,924,000 $ 18,750,000

Short-term investments 42,387,000 66,218,000

Receivables 38,000 81,000

Prepaid expenses and other current assets 3,372,000 3,802,000

Total current assets 71,721,000 88,851,000

Property and equipment, net 10,356,000 9,443,000

Right-of-use lease assets 8,749,000 0

Licensed technology, net 41,697,000 43,042,000

Goodwill 32,466,000 32,466,000

Other assets and restricted cash 1,147,000 597,000

Total assets 166,136,000 174,399,000

Current liabilities:

Accounts payable 4,189,000 6,122,000

Accrued expenses 5,241,000 3,936,000

Current portion of lease liability 1,690,000 0

Current portion of payable to licensor 10,000,000 10,000,000

Deferred revenue 296,000 296,000

Total current liabilities 21,416,000 20,354,000

Long-term lease liabilities 6,927,000 0

Payable to licensor, net of current portion 20,000,000 20,000,000

Total liabilities 48,343,000 40,354,000

Commitments and contingencies

Stockholders' equity:

Common stock - $0.01 par value; authorized 200,000,000 shares; issued and outstanding 47,949,694 at March 31, 2019; issued and outstanding 47,944,486 at December 31, 2018 479,000 479,000

Additional paid-in capital 546,057,000 543,754,000

Accumulated deficit (428,743,000) (410,188,000)

Total stockholders' equity 117,793,000 134,045,000

Total liabilities and stockholders' equity $ 166,136,000 $ 174,399,000

X

- Definition
Amount of assets classified as other and amount of cash restricted as to withdrawal or usage.
+ References
No definition available.
+ Details

Name: abeo_OtherAssetsandRestrictedCash

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount payable due to licensor.
+ References
No definition available.
+ Details

Name: abeo_PayableDueLicensorCurrent

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount less current portion of payable due to licensor.
+ References
No definition available.
+ Details

Name: abeo_PayableDueLicensorNonCurrent

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R3.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Mar. 31, 2019

Dec. 31, 2018

Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01

Common Stock, Shares Authorized 200,000,000 200,000,000

Common Stock, Shares, Issued 47,949,694 47,944,486

Common Stock, Shares, Outstanding 47,949,694 47,944,486

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 16 R4.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Revenues:

Total revenues $ 0 $ 531,000

Expenses:

Research and development 11,737,000 8,162,000

General and administrative 5,659,000 2,878,000

Depreciation and amortization 1,658,000 174,000

Total expenses 19,054,000 11,214,000

Loss from operations (19,054,000) (10,683,000)

Interest and miscellaneous income 499,000 156,000

Interest and other expense 0 (3,000)

Net loss $ (18,555,000) $ (10,530,000)

Basic and diluted loss per common share (in dollars per share) $ (0.39) $ (0.22)

Weighted average number of common shares outstanding – basic and diluted 47,948,421 47,060,523

Foundation revenues [Member]

Revenues:

Total revenues $ 0 $ 481,000

Royalties [Member]

Revenues:

Total revenues $ 0 $ 50,000

X

- Definition
Interest and other expenses associated with non operating financing activities of the entity.
+ References
No definition available.
+ Details

Name: abeo_InterestAndOtherExpense

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InvestmentIncomeNonoperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_GrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R5.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Statements of Stockholders' Equity - USD ($)

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated deficit [Member]

Balance at Dec. 31, 2017 $ 170,098,000 $ 469,000 $ 529,421,000 $ (359,792,000)

Balance (in shares) at Dec. 31, 2017 46,888,108

Cumulative effect adjustment of ASC 606 on January 1, 2018 6,275,000 $ 0 0 6,275,000

Stock-based compensation expense 1,900,000 0 1,900,000 0

Restricted stock-based compensation expense 172,000 0 172,000 0

Exercise of $5.00 warrants 144,000 $ 0 144,000 0

Exercise of $5.00 warrants (in shares) 28,874

Common stock issued for cash exercise of options 1,685,000 $ 3,000 1,682,000 0

Common stock issued for cash exercise of options (in shares) 267,196

cashless warrant exercises 0 $ 0 0 0

cashless warrant exercises (in shares) 48,762

Net loss (10,530,000) $ 0 0 (10,530,000)

Balance at Mar. 31, 2018 169,744,000 $ 472,000 533,319,000 (364,047,000)

Balance (in shares) at Mar. 31, 2018 47,232,940

Balance at Dec. 31, 2018 134,045,000 $ 479,000 543,754,000 (410,188,000)

Balance (in shares) at Dec. 31, 2018 47,944,486

Stock-based compensation expense 2,103,000 $ 0 2,103,000 0

Restricted stock-based compensation expense 172,000 0 172,000 0

Common stock issued for cash exercise of options 28,000 $ 0 28,000 0

Common stock issued for cash exercise of options (in shares) 5,208

Net loss (18,555,000) $ 0 0 (18,555,000)

Balance at Mar. 31, 2019 $ 117,793,000 $ 479,000 $ 546,057,000 $ (428,743,000)

Balance (in shares) at Mar. 31, 2019 47,949,694

X

- Definition
Value of Cashless Warrants Issued
+ References
No definition available.
+ Details

Name: abeo_NonCashOrPartNonCashAcquisitionNonCashFinancialOrEquityInstrumentConsiderationValueOfWarrantsIssued1

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of stock issued as a result of the exercise of warrants.
+ References
No definition available.
+ Details

Name: abeo_StockIssuedDuringPeriodShareswarrantsExercised

Namespace Prefix: abeo_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of warrants.
+ References
No definition available.
+ Details

Name: abeo_StockIssuedDuringPeriodValuewarrantsExercised

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cumulative effect on retained earnings net of related income tax effect.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794
+ Details

Name: us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares

Mar. 31, 2019

Mar. 31, 2018

Dollar Five Warrant [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 5.00 $ 5.00

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=abeo_DollarFiveWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Cash flows from operating activities:

Net loss $ (18,555,000) $ (10,530,000)

Adjustments to reconcile net loss to cash used in operating activities:

Depreciation and amortization 1,658,000 174,000

Stock-based compensation expense 2,103,000 1,900,000

Restricted stock-based compensation expense 172,000 172,000

Non-cash earnings on investments (169,000) 0

Change in operating assets and liabilities:

Receivables 43,000 43,000

Prepaid expenses and other current assets 430,000 643,000

Right-of-use lease assets and other assets 150,000 0

Accounts payable, accrued expenses and lease liabilities (910,000) 3,516,000

Net cash used in operating activities (15,078,000) (4,082,000)

Cash flows from investing activities:

Capital expenditures (1,226,000) (3,502,000)

Proceeds from maturities of short-term investments 24,000,000 0

Net cash provided by (used in) investing activities 22,774,000 (3,502,000)

Cash flows from financing activities:

Proceeds from exercise of stock options 28,000 1,685,000

Net cash provided by financing activities 28,000 1,829,000

Net increase (decrease) in cash, cash equivalents and restricted cash 7,724,000 (5,755,000)

Cash, cash equivalents and restricted cash at beginning of period 19,310,000 138,030,000

Cash, cash equivalents and restricted cash at end of period 27,034,000 132,275,000

Supplemental cash flow information:

Cash and cash equivalents 25,924,000 131,995,000

Restricted cash 1,110,000 280,000

Total cash, cash equivalents and restricted cash 27,034,000 132,275,000

Cash paid for interest 0 3,000

Dollar Five Warrant [Member]

Cash flows from financing activities:

Proceeds from Warrant Exercises $ 0 $ 144,000

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, restricted shares of stock, restricted unit, restricted stock options or other restricted equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
No definition available.
+ Details

Name: abeo_AllocatedShareBasedCompensationExpenseRestrictedStock

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total cash, cash equivalents and restricted cash
+ References
No definition available.
+ Details

Name: abeo_CashAndCashEquivalentsRestrictedCash

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Increase decrease in accrued expenses and lease liabilities.
+ References
No definition available.
+ Details

Name: abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents increase or decrease in right of use assets
+ References
No definition available.
+ Details

Name: abeo_IncreaseDecreaseRightOfUseAssetsAndOtherAssets

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=abeo_DollarFiveWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Statements of Cash Flows (Parenthetical) - $ / shares

Mar. 31, 2019

Mar. 31, 2018

Dollar Five Warrant [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 5.00 $ 5.00

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=abeo_DollarFiveWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.19.1

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES
NOTE 1 – NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

Background
Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”), ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”), and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We also are developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases. In addition, we are developing next generation AAV-based gene therapy though our novel AIM™ vector platform programs. Our efforts have been principally devoted to research and development, resulting in significant losses.

Basis of Presentation
The condensed consolidated balance sheet as of March 31, 2019, the condensed consolidated statements of operations for the three months ended March 31, 2019 and 2018, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2019 and 2018, and the condensed consolidated statements of cash flows for the three months ended March 31, 2019 and 2018, were prepared by management without audit. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended December 31, 2018. The results of operations for the period ended March 31, 2019 are not necessarily indicative of the operating results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2018 contains financial information taken from the audited Abeona consolidated financial statements as of that date.

As of March 31, 2019, we had
5,696,353
options and 1,820,686 warrants that were not included in the EPS calculation as their effect would be antidilutive. As of March 31, 2018, we had 5,807,531 options and 2,838,576 warrants that were not included in the EPS calculation as their effect would be antidilutive.

Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09,
Revenue from Contracts with Customers
, as amended (ASC 606). At year-end 2018, we determined that we should adjust the amounts originally reported for the quarters ended March 31, 2018 and June 30, 2018 to correct for an error in the determination of the cumulative effect related to the adoption of ASC 606 as of January 1, 2018. The adjusted amounts for March 31, 2018 reflect a $2,067,000 reduction in foundation revenues and corresponding increases in the loss from operations and net loss of $2,067,000 and an increase in the diluted loss per share of $0.04, as compared to the originally reported amounts. The adjusted amounts for June 30, 2018 reflect a $543,000 reduction in foundation revenues and corresponding increases in the loss from operations and net loss of $543,000 and an increase in the diluted loss per share of $0.01, as compared to the originally reported amounts

Uses and Sources of Liquidity
The financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.

As of March 31, 2019, we had cash, cash equivalents and short-term investments of $68.3 million and net assets of $117.8 million. For the three months ended March 31, 2019, we had cash outflows from operations of $15.1 million. We believe we have sufficient resources to fund our business operations for the foreseeable future. However, we have implemented a multi-faceted program to secure sufficient liquidity through at least the end of 2020.

This program considers the possibility of accessing additional equity funding from current or new stockholders, out-licensing technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount and sales of assets. We believe that we will be able to complete our liquidity program and will have sufficient funding to support planned expenditure commitments and our planned level of growth, and therefore we believe it is appropriate to prepare the financial statements on the going concern basis.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.19.1

NEW ACCOUNTING STANDARD IMPLEMENTED
3 Months Ended

Mar. 31, 2019

Accounting Changes and Error Corrections [Abstract]

NEW ACCOUNTING STANDARD IMPLEMENTED
NOTE 2 – NEW ACCOUNTING STANDARD IMPLEMENTED

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02,
Leases
, as amended (“ASC 842”), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. We adopted the provisions of ASC 842 effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard as of the effective date without adjusting the comparative periods presented. As a result of the adoption, we recorded operating lease right-of-use assets of $8.9 million and operating lease liabilities of $8.9 million. The adoption had an immaterial impact on our net assets as of March 31, 2019. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed us to carry forward the historical lease classification.

Additional information and disclosures required by this new standard are contained in Note 7.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.19.1

SHORT-TERM INVESTMENTS
3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

SHORT-TERM INVESTMENTS
NOTE 3 – SHORT-TERM INVESTMENTS

The following table summarizes the available-for-sale investments held:

Description

March 31,

2019

December 31,

2018

U.S. government and agency securities and treasuries

$
42,387,000

$
66,218,000

The amortized cost of the available-for-sale investments is adjusted for amortization of premiums and accretion of discounts to maturity. There were no material realized gains or losses recognized on the sale or maturity of available-for-sale investments during the three months ended March 31, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2176304
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.19.1

LICENSED TECHNOLOGY
3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

LICENSED TECHNOLOGY
NOTE 4 – LICENSED TECHNOLOGY

On November 4, 2018, we entered into a license agreement with REGENXBIO to obtain rights to an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO’s NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. In return for these rights, REGENXBIO will receive a guaranteed $20 million upfront payment, $10 million of which was paid on signing of the agreement on November 4, 2018 and $10 million of which will be paid by November 4, 2019. In addition, REGENXBIO will receive a total of $100 million in annual fees, payable upon the second through sixth anniversaries of the agreement, $20 million of which is guaranteed. REGENXBIO is also eligible to receive potential commercial milestone payments of up to $60 million as well as low double-digit royalties on net sales of products incorporating the licensed intellectual property. The license is amortized over the life of the patent of eight years.

On August 3, 2016, we announced that we entered into an agreement (the “EB Agreement”) with EB Research Partnership (“EBRP”) and Epidermolysis Bullosa Medical Research Foundation (“EBMRF”) to collaborate on gene therapy treatments for EB. The EB Agreement became effective August 3, 2016, on the execution of two licensing agreements with The Board of Trustees of Leland Stanford Junior University (“Stanford”). We also entered into a license with Stanford for the AAV-based gene therapy EB-201 (AAV DJ COL7A1) technology and are performing preclinical development and clinical trials of a gene therapy treatment for EB based upon such in-licensed technology. EB-201 (AAV DJ COL7A1) is a preclinical candidate targeting a novel, AAV-mediated gene editing and delivery approach (known as homologous recombination) to correct gene mutations in skin cells (keratinocytes) for patients with RDEB. The licenses are amortized over the life of the license of 20 years.

On May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children’s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is amortized over the life of the license of 20 years.

Licensed technology consists of the following:

March 31,

2019

December 31,

2018

Licensed technology

$
44,859,000

$
44,859,000

Less accumulated amortization

3,162,000

1,817,000

Licensed technology, net

$
41,697,000

$
43,042,000

The aggregate estimated amortization expense for intangible assets remaining as of March 31, 2019 is as follows:

2019, remainder

$
4,033,000

2020

5,378,000

2021

5,378,000

2022

5,378,000

2023

5,378,000

Thereafter

16,152,000

Total

$
41,697,000

Amortization on licensed technology was $1,345,000 and $87,000 for the three months ended March 31, 2019 and 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.19.1

FAIR VALUE MEASUREMENTS
3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS
NOTE 5 – FAIR VALUE MEASUREMENTS

We calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of receivables, prepaid expenses, other assets, accounts payable, accrued expenses, payable to licensor and deferred revenue approximate their carrying amounts due to the relatively short maturity of these instruments.

U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:


Level 1 – Quoted prices in active markets for identical assets or liabilities.


Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.


Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.

Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of March 31, 2019 and December 31, 2018 are summarized below:

Description

March 31,

2019

Level 1

Level 2

Level 3

Total

Gains/(Losses)

Recurring

Assets:

Short-term investments

$
42,387,000

$
-

$
42,387,000

$
-

$
     -

Non-recurring

Assets:

Licensed technology, net

$
41,697,000

$
-

$
-

$
41,697,000

$
-

Goodwill

32,466,000

-

-

32,466,000

-

Description

December 31,

2018

Level 1

Level 2

Level 3

Total

Gains/(Losses)

Recurring

Assets:

Short-term investments

$
66,218,000

$
-

$
66,218,000

$
-

$
     -

Non-recurring

Assets:

Licensed technology, net

$
43,042,000

$
-

$
-

$
43,042,000

$
-

Goodwill

32,466,000

-

-

32,466,000

-

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.19.1

STOCK-BASED COMPENSATION
3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION
NOTE 6 – STOCK-BASED COMPENSATION

The following table summarizes stock-based option compensation for the three months ended March 31, 2019 and 2018:

For the three months ended March 31,

2019

2018

Research and development

$
1,032,000

$
1,056,000

General and administrative

1,071,000

844,000

Stock-based compensation expense included in operating expense

2,103,000

1,900,000

Total stock-based compensation expense

2,103,000

1,900,000

Tax benefit

-

-

Stock-based compensation expense, net of tax

$
2,103,000

$
1,900,000

We estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:


Expected volatility – we estimate the volatility of our share price at the date of grant using a “look-back” period which coincided with the expected term, defined below. We believe using a “look-back” period which coincides with the expected term is the most appropriate measure for determining expected volatility.


Expected term – we estimate the expected term using the “simplified” method, as outlined in Staff Accounting Bulletin No. 107, “Share-Based Payment.”


Risk-free interest rate – we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term of the options in effect at the time of grant.


Dividends – we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare a dividend.

We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:

For the three months ended March 31,

2019

2018

Expected volatility

109
%

109
%
Expected term

5
years

5
years

Risk-free interest rate

2.46
%

2.37
%
Expected dividend yield

0
%

0
%

For the three months ended March 31, 2019, we granted 201,000 stock options and the weighted-average fair value was $5.29 and the weighted-average exercise price was $6.69. For the three months ended March 31, 2018, we granted 645,000 stock options and the weighted-average fair value was $10.83 and the weighted-average exercise price was $13.72.

The following table summarizes restricted common stock compensation expense for the three months ended March 31, 2019 and 2018:

For the three months ended March 31,

2019

2018

Research and development

$
-

$
-

General and administrative

172,000

172,000

Stock-based compensation expense included in operating expense

172,000

172,000

Total stock-based compensation expense

172,000

172,000

Tax benefit

-

-

Stock-based compensation expense, net of tax

$
172,000

$
172,000

We did not grant any common stock to directors or employees during the three months ended March 31, 2019 and 2018.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.19.1

OPERATING LEASES
3 Months Ended

Mar. 31, 2019

Leases [Abstract]

OPERATING LEASES
NOTE 7 – OPERATING LEASES

We lease space under non-cancelable operating leases for manufacturing and laboratory facilities and administrative offices in Cleveland as well as administrative offices in New York. The leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office space in Dallas and Madrid, Spain as well as certain office equipment under operating leases, which have a non-cancelable lease term of less than one year and therefore, we have elected the practical expedient to exclude these short-term leases from our right-of-use assets and lease liabilities.

Most leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal period in our lease term.

As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.

Components of lease cost are as follows:

Three months ended

March 31, 2019

Operating lease cost

$
289,000

Variable lease cost

$
73,000

Short-term lease cost

$
47,000

The following table presents information about the amount and timing of cash flows arising from operating leases as of March 31, 2019:

Maturity of lease liabilities:

2019, remainder

$
1,266,000

2020

1,699,000

2021

1,713,000

2022

1,727,000

2023

1,741,000

Thereafter

3,667,000

Total undiscounted operating lease payments

11,813,000

Less: imputed interest

3,196,000

Present value of operating lease liabilities

$
8,617,000

Balance sheet classification:

Current portion of lease liability

$
1,690,000

Long-term lease liability

6,927,000

Total operating lease liabilities

$
8,617,000

Other information:

Weighted-average remaining lease term for operating leases

82 months

Weighted-average discount rate for operating leases

9.6
%

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-URI http://asc.fasb.org/topic&trid=2208923
+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.19.1

COMMITMENTS AND CONTINGENCIES
3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES
NOTE 8 – COMMITMENTS AND CONTINGENCIES

On January 18, 2018, William Mahon, a Company stockholder, served a demand upon the Company’s board of directors (the “Board”) pursuant to Section 220 of the Delaware General Corporation Law (the “Demand”) seeking to inspect certain of the Company’s books and records. Generally, the Demand’s stated purpose was to investigate allegedly excessive compensation awarded to non-employee Board members for the fiscal years 2015–2017. The Board denied the allegations in the Demand, and agreed to provide limited books and records to Mahon. On September 17, 2018, another Company stockholder, Francisco Dos Ramos, filed a stockholder derivative complaint in the Delaware Chancery Court (the “Dos Ramos Action”) against Steven Rouhandeh, Frank Carsten Thiel, Mark Alvino, Stefano Buono, Stephen Howell, Richard Van Duyne, and Todd Wider as defendants, and the Company as nominal defendant (the “Dos Ramos Defendants”). Dos Ramos generally alleges that the Board breached its fiduciary duties, were unjustly enriched, and committed corporate waste by approving allegedly excessive compensation to non-employee Board members for the fiscal years 2015–2017. Dos Ramos generally seeks disgorgement of the allegedly improper payments to the Board, money damages, an order requiring corporate governance reforms, costs and attorneys’ fees. On November 28, 2018, Mahon filed a stockholder derivative complaint (the “Mahon Action”) in the United States District Court for the District of Delaware (the “District Court”) against Mark Ahn, Mark Alvino, Jeffrey Davis, Stephen Howell, Todd Wider, and Steven Rouhandeh, as defendants, and the Company as a nominal defendant (“Mahon Defendants”). The allegations in the Mahon Action are substantially similar to those set forth in his Demand, as well as those in the Dos Ramos Action. Mahon generally seeks the disgorgement of the allegedly improper payments to the Board, a constructive trust, money damages, costs and attorneys’ fees. On December 6, 2018, Mahon and the Mahon Defendants filed a joint motion for preliminary approval of settlement, along with a stipulation of settlement (the “Stipulation”) intending to settle all claims asserted in the Mahon Action.

On January 8, 2019, the District Court approved the parties’ notice of settlement, enjoining all Company stockholders from commencing or further prosecuting any claims asserted in the Mahon Action, and scheduled a settlement approval hearing for May 1, 2019. On January 25, 2019, the Chancery Court entered an order staying the Dos Ramos Action until May 8, 2019—one week after the May 1, 2019 settlement hearing in the Mahon Action. On May 2, 2019 the District Court entered an Order and Final Judgment approving the Stipulation.

On October 22, 2018, EB Research Partnership, Inc. (“EBRP”) served upon the Company a Request for Arbitration (the “Request”), alleging that the Company is in breach of an Agreement executed in July 2016 (the “Agreement”) between and among the Company, EBRP, and Epidermolysis Bullosa Medical Research Foundation (“EBMRF”). EBRP alleges that Abeona has refused to lift trading restrictions on certain shares of Abeona common stock issued to EBRP, purportedly in breach of the Agreement. On November 21, 2018, the Company filed an action in the United States District Court for the Southern District of New York seeking a declaration that it is not required to arbitrate its dispute with EBRP on the basis that the Agreement is void for lack of consideration. On February 4, 2019, the court granted EBRP and EBMRF’s motion to compel arbitration. EBMRF was subsequently joined as a party to the arbitration. The parties submitted briefs to the arbitrator on March 18 and April 18, 2019. The dispute is pending before the arbitrator and a decision is expected on or before May 20, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.19.1

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Background
Background
Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”), ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”), and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We also are developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases. In addition, we are developing next generation AAV-based gene therapy though our novel AIM™ vector platform programs. Our efforts have been principally devoted to research and development, resulting in significant losses.

Basis of Presentation
Basis of Presentation
The condensed consolidated balance sheet as of March 31, 2019, the condensed consolidated statements of operations for the three months ended March 31, 2019 and 2018, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2019 and 2018, and the condensed consolidated statements of cash flows for the three months ended March 31, 2019 and 2018, were prepared by management without audit. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended December 31, 2018. The results of operations for the period ended March 31, 2019 are not necessarily indicative of the operating results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2018 contains financial information taken from the audited Abeona consolidated financial statements as of that date.

As of March 31, 2019, we had
5,696,353
options and 1,820,686 warrants that were not included in the EPS calculation as their effect would be antidilutive. As of March 31, 2018, we had 5,807,531 options and 2,838,576 warrants that were not included in the EPS calculation as their effect would be antidilutive.

Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09,
Revenue from Contracts with Customers
, as amended (ASC 606). At year-end 2018, we determined that we should adjust the amounts originally reported for the quarters ended March 31, 2018 and June 30, 2018 to correct for an error in the determination of the cumulative effect related to the adoption of ASC 606 as of January 1, 2018. The adjusted amounts for March 31, 2018 reflect a $2,067,000 reduction in foundation revenues and corresponding increases in the loss from operations and net loss of $2,067,000 and an increase in the diluted loss per share of $0.04, as compared to the originally reported amounts. The adjusted amounts for June 30, 2018 reflect a $543,000 reduction in foundation revenues and corresponding increases in the loss from operations and net loss of $543,000 and an increase in the diluted loss per share of $0.01, as compared to the originally reported amounts

Uses and Sources of Liquidity
Uses and Sources of Liquidity
The financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.

As of March 31, 2019, we had cash, cash equivalents and short-term investments of $68.3 million and net assets of $117.8 million. For the three months ended March 31, 2019, we had cash outflows from operations of $15.1 million. We believe we have sufficient resources to fund our business operations for the foreseeable future. However, we have implemented a multi-faceted program to secure sufficient liquidity through at least the end of 2020.

This program considers the possibility of accessing additional equity funding from current or new stockholders, out-licensing technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount and sales of assets. We believe that we will be able to complete our liquidity program and will have sufficient funding to support planned expenditure commitments and our planned level of growth, and therefore we believe it is appropriate to prepare the financial statements on the going concern basis.

X

- Definition
Disclosure of accounting policy for business description. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.
+ References
No definition available.
+ Details

Name: abeo_NatureOfOperationsPolicyTextBlock

Namespace Prefix: abeo_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.19.1

SHORT-TERM INVESTMENTS (Tables)
3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Schedule of available-for-sale investments held
The following table summarizes the available-for-sale investments held:

Description

March 31,

2019

December 31,

2018

U.S. government and agency securities and treasuries

$
42,387,000

$
66,218,000

X

- Definition
Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.19.1

LICENSED TECHNOLOGY (Tables)
3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of licensed technology
Licensed technology consists of the following:

March 31,

2019

December 31,

2018

Licensed technology

$
44,859,000

$
44,859,000

Less accumulated amortization

3,162,000

1,817,000

Licensed technology, net

$
41,697,000

$
43,042,000

Amortization expense for intangible assets
The aggregate estimated amortization expense for intangible assets remaining as of March 31, 2019 is as follows:

2019, remainder

$
4,033,000

2020

5,378,000

2021

5,378,000

2022

5,378,000

2023

5,378,000

Thereafter

16,152,000

Total

$
41,697,000

X

- Definition
Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.19.1

FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Financial assets and liabilities measured at fair value on recurring basis
Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of March 31, 2019 and December 31, 2018 are summarized below:

Description

March 31,

2019

Level 1

Level 2

Level 3

Total

Gains/(Losses)

Recurring

Assets:

Short-term investments

$
42,387,000

$
-

$
42,387,000

$
-

$
     -

Non-recurring

Assets:

Licensed technology, net

$
41,697,000

$
-

$
-

$
41,697,000

$
-

Goodwill

32,466,000

-

-

32,466,000

-

Description

December 31,

2018

Level 1

Level 2

Level 3

Total

Gains/(Losses)

Recurring

Assets:

Short-term investments

$
66,218,000

$
-

$
66,218,000

$
-

$
     -

Non-recurring

Assets:

Licensed technology, net

$
43,042,000

$
-

$
-

$
43,042,000

$
-

Goodwill

32,466,000

-

-

32,466,000

-

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.19.1

STOCK-BASED COMPENSATION (Tables)
3 Months Ended

Mar. 31, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of weighted-average assumptions to estimate the fair value of the options granted
We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:

For the three months ended March 31,

2019

2018

Expected volatility

109
%

109
%
Expected term

5
years

5
years

Risk-free interest rate

2.46
%

2.37
%
Expected dividend yield

0
%

0
%

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summarization of stock-based compensation
The following table summarizes stock-based option compensation for the three months ended March 31, 2019 and 2018:

For the three months ended March 31,

2019

2018

Research and development

$
1,032,000

$
1,056,000

General and administrative

1,071,000

844,000

Stock-based compensation expense included in operating expense

2,103,000

1,900,000

Total stock-based compensation expense

2,103,000

1,900,000

Tax benefit

-

-

Stock-based compensation expense, net of tax

$
2,103,000

$
1,900,000

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summarization of stock-based compensation
The following table summarizes restricted common stock compensation expense for the three months ended March 31, 2019 and 2018:

For the three months ended March 31,

2019

2018

Research and development

$
-

$
-

General and administrative

172,000

172,000

Stock-based compensation expense included in operating expense

172,000

172,000

Total stock-based compensation expense

172,000

172,000

Tax benefit

-

-

Stock-based compensation expense, net of tax

$
172,000

$
172,000

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.19.1

OPERATING LEASES (Tables)
3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Components of lease cost
Components of lease cost are as follows:

Three months ended

March 31, 2019

Operating lease cost

$
289,000

Variable lease cost

$
73,000

Short-term lease cost

$
47,000

Schedule Of Supplemental Cash Flow Information Related To Leases
The following table presents information about the amount and timing of cash flows arising from operating leases as of March 31, 2019:

Maturity of lease liabilities:

2019, remainder

$
1,266,000

2020

1,699,000

2021

1,713,000

2022

1,727,000

2023

1,741,000

Thereafter

3,667,000

Total undiscounted operating lease payments

11,813,000

Less: imputed interest

3,196,000

Present value of operating lease liabilities

$
8,617,000

Balance sheet classification:

Current portion of lease liability

$
1,690,000

Long-term lease liability

6,927,000

Total operating lease liabilities

$
8,617,000

Other information:

Weighted-average remaining lease term for operating leases

82 months

Weighted-average discount rate for operating leases

9.6
%

X

- Definition
Schedule of supplemental cash flow information related to leases
+ References
No definition available.
+ Details

Name: abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock

Namespace Prefix: abeo_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.19.1

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)
3 Months Ended

Mar. 31, 2019

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2018

Dec. 31, 2017

Cash, Cash Equivalents, and Short-term Investments $ 68,300,000

Stockholders' Equity Attributable to Parent 117,793,000 $ 169,744,000 $ 134,045,000 $ 170,098,000

Net Cash Provided by (Used in) Operating Activities $ (15,078,000) (4,082,000)

New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Operating Results $ 543,000 2,067,000

New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification $ 543,000 $ 2,067,000

New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Diluted Earnings Per Share $ 0.01 $ 0.04

Employee Stock Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,696,353 5,807,531

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,820,686 2,838,576

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the effect of a change in accounting principle on diluted earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1278-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnDilutedEarningsPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the effect of a change in accounting principle on operating profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnOperatingResults

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.19.1

NEW ACCOUNTING STANDARD IMPLEMENTED (Details Textual)

Mar. 31, 2019

USD ($)

Operating Lease, Liability $ 8,617,000

Operating Lease, Right-of-Use Asset $ 8,900,000

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.19.1

SHORT-TERM INVESTMENTS (Details) - USD ($)

Mar. 31, 2019

Dec. 31, 2018

Debt Securities, Available-for-sale $ 42,387,000 $ 66,218,000

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.19.1

LICENSED TECHNOLOGY (Details) - USD ($)

Mar. 31, 2019

Dec. 31, 2018

Licensed technology $ 44,859,000 $ 44,859,000

Less accumulated amortization 3,162,000 1,817,000

Licensed technology, net $ 41,697,000 $ 43,042,000

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.19.1

LICENSED TECHNOLOGY (Details 1) - USD ($)

Mar. 31, 2019

Dec. 31, 2018

2019 $ 4,033,000

2020 5,378,000

2021 5,378,000

2022 5,378,000

2023 5,378,000

Thereafter 16,152,000

Total $ 41,697,000 $ 43,042,000

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.19.1

LICENSED TECHNOLOGY (Details Textual) - USD ($)
1 Months Ended 3 Months Ended

Nov. 04, 2018

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Finite-Lived Intangible Asset, Useful Life 20 years

Payable Due Licensor Non current $ 20,000,000 $ 20,000,000

Amortization of Intangible Assets 1,345,000 $ 87,000

Payable Due Licensor Current $ 10,000,000 $ 10,000,000

Abeona Therapeutics LLC [Member]

Finite-Lived Intangible Asset, Useful Life 20 years

REGENXBIO [Member] | Licensing Agreements [Member]

Payable Due Licensor Non current $ 20,000,000

Guaranteed Upfront Payment 20,000,000

Payment on Execution of Contracts 10,000,000

Annual Fees 100,000,000

Milestone Payment 60,000,000

Payable Due Licensor Current $ 10,000,000

X

- Definition
Represents the total annual fees payable on the contract.
+ References
No definition available.
+ Details

Name: abeo_AnnualFees

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of upfront payment to be made.
+ References
No definition available.
+ Details

Name: abeo_GuaranteedUpfrontPayment

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount to be paid on future date on the completion of certain milestone on the contract.
+ References
No definition available.
+ Details

Name: abeo_MilestonePayment

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount payable due to licensor.
+ References
No definition available.
+ Details

Name: abeo_PayableDueLicensorCurrent

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount less current portion of payable due to licensor.
+ References
No definition available.
+ Details

Name: abeo_PayableDueLicensorNonCurrent

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount to be paid on the execution of contracts under the license agreement.
+ References
No definition available.
+ Details

Name: abeo_PaymentOnExecutionOfContracts

Namespace Prefix: abeo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abeo_AbeonaTherapeuticsLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=abeo_REGENXBIOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.19.1

FAIR VALUE MEASUREMENTS (Details) - USD ($)

Mar. 31, 2019

Dec. 31, 2018

Assets

Short-term Investments $ 42,387,000 $ 66,218,000

Nonrecurring [Member]

Assets

Licensed technology (net) 41,697,000 43,042,000

Goodwill 32,466,000 32,466,000

Nonrecurring [Member] | Licensed technology [Member]

Assets

Licensed technology (net) 0 0

Nonrecurring [Member] | Licensed technology [Member] | Fair Value, Inputs, Level 1 [Member]

Assets

Licensed technology (net) 0 0

Nonrecurring [Member] | Licensed technology [Member] | Fair Value, Inputs, Level 2 [Member]

Assets

Licensed technology (net) 0 0

Nonrecurring [Member] | Licensed technology [Member] | Fair Value, Inputs, Level 3 [Member]

Assets

Licensed technology (net) 41,697,000 43,042,000

Nonrecurring [Member] | Goodwill [Member]

Assets

Goodwill 0 0

Nonrecurring [Member] | Goodwill [Member] | Fair Value, Inputs, Level 1 [Member]

Assets

Goodwill 0 0

Nonrecurring [Member] | Goodwill [Member] | Fair Value, Inputs, Level 2 [Member]

Assets

Goodwill 0 0

Nonrecurring [Member] | Goodwill [Member] | Fair Value, Inputs, Level 3 [Member]

Assets

Goodwill 32,466,000 32,466,000

Recurring Member

Assets

Short-term Investments 42,387,000 66,218,000

Recurring Member | Available-for-sale Securities [Member] | Fair Value, Inputs, Level 1 [Member]

Assets

Short-term Investments 0 0

Recurring Member | Available-for-sale Securities [Member] | Fair Value, Inputs, Level 2 [Member]

Assets

Short-term Investments 42,387,000 66,218,000

Recurring Member | Available-for-sale Securities [Member] | Fair Value, Inputs, Level 3 [Member]

Assets

Short-term Investments $ 0 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258
+ Details

Name: us-gaap_GoodwillFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_AvailableforsaleSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.19.1

STOCK-BASED COMPENSATION (Details) - USD ($)
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-based compensation expense included in operating expense $ 2,103,000 $ 1,900,000

Total stock-based compensation expense 2,103,000 1,900,000

Stock Options [Member]

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-based compensation expense included in operating expense 2,103,000 1,900,000

Total stock-based compensation expense 2,103,000 1,900,000

Tax benefit 0 0

Stock-based compensation expense, net of tax 2,103,000 1,900,000

Stock Options [Member] | Research and Development Expense [Member]

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-based compensation expense included in operating expense 1,032,000 1,056,000

Total stock-based compensation expense 1,032,000 1,056,000

Stock Options [Member] | General and Administrative [Member]

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-based compensation expense included in operating expense 1,071,000 844,000

Total stock-based compensation expense 1,071,000 844,000

Restricted Stock [Member]

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-based compensation expense included in operating expense 172,000 172,000

Total stock-based compensation expense 172,000 172,000

Tax benefit 0 0

Stock-based compensation expense, net of tax 172,000 172,000

Restricted Stock [Member] | Research and Development Expense [Member]

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-based compensation expense included in operating expense 0 0

Total stock-based compensation expense 0 0

Restricted Stock [Member] | General and Administrative [Member]

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-based compensation expense included in operating expense 172,000 172,000

Total stock-based compensation expense $ 172,000 $ 172,000

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
No definition available.
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.19.1

STOCK-BASED COMPENSATION (Details 1)
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Expected volatility 109.00% 109.00%

Expected term 5 years 5 years

Risk-free interest rate 2.46% 2.37%

Expected dividend yield 0.00% 0.00%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.19.1

STOCK-BASED COMPENSATION (Details Textual) - $ / shares
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 5.29 $ 10.83

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price $ 6.69 $ 13.72

Stock Options [Member]

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 201,000 645,000

X

- Definition
Agreed-upon share price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice

Namespace Prefix: abeo_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.19.1

OPERATING LEASES (Details)
3 Months Ended

Mar. 31, 2019

USD ($)

Operating lease cost $ 289,000

Variable lease cost 73,000

Short-term lease cost $ 47,000

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of short-term lease cost, excluding expense for lease with term of one month or less.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_ShortTermLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_VariableLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.19.1

OPERATING LEASES (Details 1)

Mar. 31, 2019

USD ($)

Maturity of lease liabilities:

2019, remainder $ 1,266,000

2020 1,699,000

2021 1,713,000

2022 1,727,000

2023 1,741,000

Thereafter 3,667,000

Total undiscounted operating lease payments 11,813,000

Less: imputed interest 3,196,000

Total operating lease liabilities 8,617,000

Balance sheet classification:

Current portion of lease liability 1,690,000

Long-term lease liability 6,927,000

Total operating lease liabilities $ 8,617,000

Other information:

Weighted-average remaining lease term for operating leases 82 months

Weighted-average discount rate for operating leases 9.60%

X

- References
No definition available.
+ Details

Name: abeo_BalanceSheetClassificationAbstract

Namespace Prefix: abeo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: abeo_OtherInformationAbstract

Namespace Prefix: abeo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 79 151 1 false 23 0 false 4 false false R1.htm 1001 - Document - Document and Entity Information Sheet http://abeonatherapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://abeonatherapeutics.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://abeonatherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations Sheet http://abeonatherapeutics.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://abeonatherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://abeonatherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://abeonatherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 1008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://abeonatherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 8 false false R9.htm 1009 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 1010 - Disclosure - NEW ACCOUNTING STANDARD IMPLEMENTED Sheet http://abeonatherapeutics.com/role/NewAccountingStandardImplemented NEW ACCOUNTING STANDARD IMPLEMENTED Notes 10 false false R11.htm 1011 - Disclosure - SHORT-TERM INVESTMENTS Sheet http://abeonatherapeutics.com/role/ShortTermInvestments SHORT-TERM INVESTMENTS Notes 11 false false R12.htm 1012 - Disclosure - LICENSED TECHNOLOGY Sheet http://abeonatherapeutics.com/role/LicensedTechnology LICENSED TECHNOLOGY Notes 12 false false R13.htm 1013 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://abeonatherapeutics.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 1014 - Disclosure - STOCK-BASED COMPENSATION Sheet http://abeonatherapeutics.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 14 false false R15.htm 1015 - Disclosure - OPERATING LEASES Sheet http://abeonatherapeutics.com/role/OperatingLeases OPERATING LEASES Notes 15 false false R16.htm 1016 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://abeonatherapeutics.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 1017 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 1018 - Disclosure - SHORT-TERM INVESTMENTS (Tables) Sheet http://abeonatherapeutics.com/role/ShortTermInvestmentsTables SHORT-TERM INVESTMENTS (Tables) Tables http://abeonatherapeutics.com/role/ShortTermInvestments 18 false false R19.htm 1019 - Disclosure - LICENSED TECHNOLOGY (Tables) Sheet http://abeonatherapeutics.com/role/LicensedTechnologyTables LICENSED TECHNOLOGY (Tables) Tables http://abeonatherapeutics.com/role/LicensedTechnology 19 false false R20.htm 1020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://abeonatherapeutics.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://abeonatherapeutics.com/role/FairValueMeasurements 20 false false R21.htm 1021 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://abeonatherapeutics.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://abeonatherapeutics.com/role/StockBasedCompensation 21 false false R22.htm 1022 - Disclosure - OPERATING LEASES (Tables) Sheet http://abeonatherapeutics.com/role/OperatingLeasesTables OPERATING LEASES (Tables) Tables http://abeonatherapeutics.com/role/OperatingLeases 22 false false R23.htm 1023 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsTextual NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Details http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies 23 false false R24.htm 1024 - Disclosure - NEW ACCOUNTING STANDARD IMPLEMENTED (Details Textual) Sheet http://abeonatherapeutics.com/role/NewAccountingStandardImplementedDetailsTextual NEW ACCOUNTING STANDARD IMPLEMENTED (Details Textual) Details http://abeonatherapeutics.com/role/NewAccountingStandardImplemented 24 false false R25.htm 1025 - Disclosure - SHORT-TERM INVESTMENTS (Details) Sheet http://abeonatherapeutics.com/role/ShortTermInvestmentsDetails SHORT-TERM INVESTMENTS (Details) Details http://abeonatherapeutics.com/role/ShortTermInvestmentsTables 25 false false R26.htm 1026 - Disclosure - LICENSED TECHNOLOGY (Details) Sheet http://abeonatherapeutics.com/role/LicensedTechnologyDetails LICENSED TECHNOLOGY (Details) Details http://abeonatherapeutics.com/role/LicensedTechnologyTables 26 false false R27.htm 1027 - Disclosure - LICENSED TECHNOLOGY (Details 1) Sheet http://abeonatherapeutics.com/role/LicensedTechnologyDetails1 LICENSED TECHNOLOGY (Details 1) Details http://abeonatherapeutics.com/role/LicensedTechnologyTables 27 false false R28.htm 1028 - Disclosure - LICENSED TECHNOLOGY (Details Textual) Sheet http://abeonatherapeutics.com/role/LicensedTechnologyDetailsTextual LICENSED TECHNOLOGY (Details Textual) Details http://abeonatherapeutics.com/role/LicensedTechnologyTables 28 false false R29.htm 1029 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://abeonatherapeutics.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://abeonatherapeutics.com/role/FairValueMeasurementsTables 29 false false R30.htm 1030 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://abeonatherapeutics.com/role/StockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://abeonatherapeutics.com/role/StockBasedCompensationTables 30 false false R31.htm 1031 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://abeonatherapeutics.com/role/StockBasedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://abeonatherapeutics.com/role/StockBasedCompensationTables 31 false false R32.htm 1032 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) Sheet http://abeonatherapeutics.com/role/StockBasedCompensationDetailsTextual STOCK-BASED COMPENSATION (Details Textual) Details http://abeonatherapeutics.com/role/StockBasedCompensationTables 32 false false R33.htm 1033 - Disclosure - OPERATING LEASES (Details) Sheet http://abeonatherapeutics.com/role/OperatingLeasesDetails OPERATING LEASES (Details) Details http://abeonatherapeutics.com/role/OperatingLeasesTables 33 false false R34.htm 1034 - Disclosure - OPERATING LEASES (Details 1) Sheet http://abeonatherapeutics.com/role/OperatingLeasesDetails1 OPERATING LEASES (Details 1) Details http://abeonatherapeutics.com/role/OperatingLeasesTables 34 false false All Reports Book All Reports abeo-20190331.xml abeo-20190331.xsd abeo-20190331_cal.xml abeo-20190331_def.xml abeo-20190331_lab.xml abeo-20190331_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 52 0001144204-19-025271-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-19-025271-xbrl.zip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end

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 06, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Registrant Name	ABEONA THERAPEUTICS INC.
Entity Central Index Key	0000318306
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	ABEO
Entity Common Stock, Shares Outstanding		49,162,047
Entity Emerging Growth Company	false
Entity Small Business	true

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 25,924,000	$ 18,750,000
Short-term investments	42,387,000	66,218,000
Receivables	38,000	81,000
Prepaid expenses and other current assets	3,372,000	3,802,000
Total current assets	71,721,000	88,851,000
Property and equipment, net	10,356,000	9,443,000
Right-of-use lease assets	8,749,000	0
Licensed technology, net	41,697,000	43,042,000
Goodwill	32,466,000	32,466,000
Other assets and restricted cash	1,147,000	597,000
Total assets	166,136,000	174,399,000
Current liabilities:
Accounts payable	4,189,000	6,122,000
Accrued expenses	5,241,000	3,936,000
Current portion of lease liability	1,690,000	0
Current portion of payable to licensor	10,000,000	10,000,000
Deferred revenue	296,000	296,000
Total current liabilities	21,416,000	20,354,000
Long-term lease liabilities	6,927,000	0
Payable to licensor, net of current portion	20,000,000	20,000,000
Total liabilities	48,343,000	40,354,000
Commitments and contingencies
Stockholders' equity:
Common stock - $0.01 par value; authorized 200,000,000 shares; issued and outstanding 47,949,694 at March 31, 2019; issued and outstanding 47,944,486 at December 31, 2018	479,000	479,000
Additional paid-in capital	546,057,000	543,754,000
Accumulated deficit	(428,743,000)	(410,188,000)
Total stockholders' equity	117,793,000	134,045,000
Total liabilities and stockholders' equity	$ 166,136,000	$ 174,399,000

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	47,949,694	47,944,486
Common Stock, Shares, Outstanding	47,949,694	47,944,486

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Total revenues	$ 0	$ 531,000
Expenses:
Research and development	11,737,000	8,162,000
General and administrative	5,659,000	2,878,000
Depreciation and amortization	1,658,000	174,000
Total expenses	19,054,000	11,214,000
Loss from operations	(19,054,000)	(10,683,000)
Interest and miscellaneous income	499,000	156,000
Interest and other expense	0	(3,000)
Net loss	$ (18,555,000)	$ (10,530,000)
Basic and diluted loss per common share (in dollars per share)	$ (0.39)	$ (0.22)
Weighted average number of common shares outstanding – basic and diluted	47,948,421	47,060,523
Foundation revenues [Member]
Revenues:
Total revenues	$ 0	$ 481,000
Royalties [Member]
Revenues:
Total revenues	$ 0	$ 50,000

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]
Balance at Dec. 31, 2017	$ 170,098,000	$ 469,000	$ 529,421,000	$ (359,792,000)
Balance (in shares) at Dec. 31, 2017		46,888,108
Cumulative effect adjustment of ASC 606 on January 1, 2018	6,275,000	$ 0	0	6,275,000
Stock-based compensation expense	1,900,000	0	1,900,000	0
Restricted stock-based compensation expense	172,000	0	172,000	0
Exercise of $5.00 warrants	144,000	$ 0	144,000	0
Exercise of $5.00 warrants (in shares)		28,874
Common stock issued for cash exercise of options	1,685,000	$ 3,000	1,682,000	0
Common stock issued for cash exercise of options (in shares)		267,196
cashless warrant exercises	0	$ 0	0	0
cashless warrant exercises (in shares)		48,762
Net loss	(10,530,000)	$ 0	0	(10,530,000)
Balance at Mar. 31, 2018	169,744,000	$ 472,000	533,319,000	(364,047,000)
Balance (in shares) at Mar. 31, 2018		47,232,940
Balance at Dec. 31, 2018	134,045,000	$ 479,000	543,754,000	(410,188,000)
Balance (in shares) at Dec. 31, 2018		47,944,486
Stock-based compensation expense	2,103,000	$ 0	2,103,000	0
Restricted stock-based compensation expense	172,000	0	172,000	0
Common stock issued for cash exercise of options	28,000	$ 0	28,000	0
Common stock issued for cash exercise of options (in shares)		5,208
Net loss	(18,555,000)	$ 0	0	(18,555,000)
Balance at Mar. 31, 2019	$ 117,793,000	$ 479,000	$ 546,057,000	$ (428,743,000)
Balance (in shares) at Mar. 31, 2019		47,949,694

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	Mar. 31, 2019	Mar. 31, 2018
Dollar Five Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.00	$ 5.00

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (18,555,000)	$ (10,530,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	1,658,000	174,000
Stock-based compensation expense	2,103,000	1,900,000
Restricted stock-based compensation expense	172,000	172,000
Non-cash earnings on investments	(169,000)	0
Change in operating assets and liabilities:
Receivables	43,000	43,000
Prepaid expenses and other current assets	430,000	643,000
Right-of-use lease assets and other assets	150,000	0
Accounts payable, accrued expenses and lease liabilities	(910,000)	3,516,000
Net cash used in operating activities	(15,078,000)	(4,082,000)
Cash flows from investing activities:
Capital expenditures	(1,226,000)	(3,502,000)
Proceeds from maturities of short-term investments	24,000,000	0
Net cash provided by (used in) investing activities	22,774,000	(3,502,000)
Cash flows from financing activities:
Proceeds from exercise of stock options	28,000	1,685,000
Net cash provided by financing activities	28,000	1,829,000
Net increase (decrease) in cash, cash equivalents and restricted cash	7,724,000	(5,755,000)
Cash, cash equivalents and restricted cash at beginning of period	19,310,000	138,030,000
Cash, cash equivalents and restricted cash at end of period	27,034,000	132,275,000
Supplemental cash flow information:
Cash and cash equivalents	25,924,000	131,995,000
Restricted cash	1,110,000	280,000
Total cash, cash equivalents and restricted cash	27,034,000	132,275,000
Cash paid for interest	0	3,000
Dollar Five Warrant [Member]
Cash flows from financing activities:
Proceeds from Warrant Exercises	$ 0	$ 144,000

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Cash, Cash Equivalents, and Short-term Investments	$ 68,300,000
Stockholders' Equity Attributable to Parent	117,793,000		$ 169,744,000	$ 134,045,000	$ 170,098,000
Net Cash Provided by (Used in) Operating Activities	$ (15,078,000)		(4,082,000)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Operating Results		$ 543,000	2,067,000
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification		$ 543,000	$ 2,067,000
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Diluted Earnings Per Share		$ 0.01	$ 0.04
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,696,353		5,807,531
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,820,686		2,838,576

NEW ACCOUNTING STANDARD IMPLEMENTED (Details Textual)	Mar. 31, 2019 USD ($)
Operating Lease, Liability	$ 8,617,000
Operating Lease, Right-of-Use Asset	$ 8,900,000

LICENSED TECHNOLOGY (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Licensed technology	$ 44,859,000	$ 44,859,000
Less accumulated amortization	3,162,000	1,817,000
Licensed technology, net	$ 41,697,000	$ 43,042,000

LICENSED TECHNOLOGY (Details 1) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
2019	$ 4,033,000
2020	5,378,000
2021	5,378,000
2022	5,378,000
2023	5,378,000
Thereafter	16,152,000
Total	$ 41,697,000	$ 43,042,000

LICENSED TECHNOLOGY (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
LICENSED TECHNOLOGY (Details Textual) - USD ($)	Nov. 04, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Finite-Lived Intangible Asset, Useful Life		20 years
Payable Due Licensor Non current		$ 20,000,000		$ 20,000,000
Amortization of Intangible Assets		1,345,000	$ 87,000
Payable Due Licensor Current		$ 10,000,000		$ 10,000,000
Abeona Therapeutics LLC [Member]
Finite-Lived Intangible Asset, Useful Life		20 years
REGENXBIO [Member] \| Licensing Agreements [Member]
Payable Due Licensor Non current	$ 20,000,000
Guaranteed Upfront Payment	20,000,000
Payment on Execution of Contracts	10,000,000
Annual Fees	100,000,000
Milestone Payment	60,000,000
Payable Due Licensor Current	$ 10,000,000

FAIR VALUE MEASUREMENTS (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Assets
Short-term Investments	$ 42,387,000	$ 66,218,000
Nonrecurring [Member]
Assets
Licensed technology (net)	41,697,000	43,042,000
Goodwill	32,466,000	32,466,000
Nonrecurring [Member] \| Licensed technology [Member]
Assets
Licensed technology (net)	0	0
Nonrecurring [Member] \| Licensed technology [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets
Licensed technology (net)	0	0
Nonrecurring [Member] \| Licensed technology [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets
Licensed technology (net)	0	0
Nonrecurring [Member] \| Licensed technology [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets
Licensed technology (net)	41,697,000	43,042,000
Nonrecurring [Member] \| Goodwill [Member]
Assets
Goodwill	0	0
Nonrecurring [Member] \| Goodwill [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets
Goodwill	0	0
Nonrecurring [Member] \| Goodwill [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets
Goodwill	0	0
Nonrecurring [Member] \| Goodwill [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets
Goodwill	32,466,000	32,466,000
Recurring Member
Assets
Short-term Investments	42,387,000	66,218,000
Recurring Member \| Available-for-sale Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets
Short-term Investments	0	0
Recurring Member \| Available-for-sale Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets
Short-term Investments	42,387,000	66,218,000
Recurring Member \| Available-for-sale Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets
Short-term Investments	$ 0	$ 0

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Stock-based compensation expense included in operating expense	$ 2,103,000	$ 1,900,000
Total stock-based compensation expense	2,103,000	1,900,000
Stock Options [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Stock-based compensation expense included in operating expense	2,103,000	1,900,000
Total stock-based compensation expense	2,103,000	1,900,000
Tax benefit	0	0
Stock-based compensation expense, net of tax	2,103,000	1,900,000
Stock Options [Member] \| Research and Development Expense [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Stock-based compensation expense included in operating expense	1,032,000	1,056,000
Total stock-based compensation expense	1,032,000	1,056,000
Stock Options [Member] \| General and Administrative [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Stock-based compensation expense included in operating expense	1,071,000	844,000
Total stock-based compensation expense	1,071,000	844,000
Restricted Stock [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Stock-based compensation expense included in operating expense	172,000	172,000
Total stock-based compensation expense	172,000	172,000
Tax benefit	0	0
Stock-based compensation expense, net of tax	172,000	172,000
Restricted Stock [Member] \| Research and Development Expense [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Stock-based compensation expense included in operating expense	0	0
Total stock-based compensation expense	0	0
Restricted Stock [Member] \| General and Administrative [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Stock-based compensation expense included in operating expense	172,000	172,000
Total stock-based compensation expense	$ 172,000	$ 172,000

STOCK-BASED COMPENSATION (Details 1)	3 Months Ended
STOCK-BASED COMPENSATION (Details 1)	Mar. 31, 2019	Mar. 31, 2018
Expected volatility	109.00%	109.00%
Expected term	5 years	5 years
Risk-free interest rate	2.46%	2.37%
Expected dividend yield	0.00%	0.00%

STOCK-BASED COMPENSATION (Details Textual) - $ / shares	3 Months Ended
STOCK-BASED COMPENSATION (Details Textual) - $ / shares	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 5.29	$ 10.83
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price	$ 6.69	$ 13.72
Stock Options [Member]
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	201,000	645,000

OPERATING LEASES (Details)	3 Months Ended
OPERATING LEASES (Details)	Mar. 31, 2019 USD ($)
Operating lease cost	$ 289,000
Variable lease cost	73,000
Short-term lease cost	$ 47,000

OPERATING LEASES (Details 1)	Mar. 31, 2019 USD ($)
Maturity of lease liabilities:
2019, remainder	$ 1,266,000
2020	1,699,000
2021	1,713,000
2022	1,727,000
2023	1,741,000
Thereafter	3,667,000
Total undiscounted operating lease payments	11,813,000
Less: imputed interest	3,196,000
Total operating lease liabilities	8,617,000
Balance sheet classification:
Current portion of lease liability	1,690,000
Long-term lease liability	6,927,000
Total operating lease liabilities	$ 8,617,000
Other information:
Weighted-average remaining lease term for operating leases	82 months
Weighted-average discount rate for operating leases	9.60%